MSKA & Associates Chartered Accountants

SV Tower, No. 27, Floor 4 80 Feet Road, 6th Block, Koramangala, Bengaluru 560095, INDIA Tel: +91 80 6811 1600

INDEPENDENT AUDITOR'S REPORT

To the Members of Medi Assist Healthcare Services Limited Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Medi Assist Healthcare Services Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated balance sheet as at March 31, 2022, and the consolidated statement of profit and loss, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on consideration of reports of other auditors on separate financial statements and on the other financial information of subsidiaries, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group as at March 31, 2022, of consolidated profit, consolidated changes in equity and its consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, its associate and jointly controlled entities in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by Institute of Chartered Accountant of India ("ICAI"), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

MSKA & Associates Chartered Accountants

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.

Other Matters

ASSOC

The Consolidated Ind AS financial statements of the Company for the year ended March 31, 2021, were adopted by the Board of Directors, on which the previous auditor issued a disclaimer of opinion dated November 23, 2021.

Our opinion is not modified in respect of this matter.

Report on Other Legal and Regulatory Requirements

- 1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

MSKA & Associates

Chartered Accountants

- b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.
- c. The consolidated balance sheet, the consolidated statement of profit and loss, the consolidated statement of changes in equity and the consolidated statement of cash flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- d. In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors of the Holding Company and our audit report on the statutory audit of its subsidiary company incorporated in India, none of the directors of the Group companies, are disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - The consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group- Refer Note 27 to the consolidated financial statements.
 - The Group has long-term contracts as on March 31, 2022, for which there were no material foreseeable losses. The Group did not have any derivative contracts as on March 31, 2022.
 - There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company and its subsidiary companies incorporated in India.
 - iv. On the basis of our verification, we report that:
 - The final dividend paid by the Holding Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Companies Act 2013 to the extent it applies to payment of dividend.
 - The Board of Directors of the Holding Company has proposed final dividend for the year which is subject to the approval of their respective members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend. (Refer Note 13 to the consolidated financial statements)



MSKA & Associates

Chartered Accountants

- As required by the Companies (Amendment) Act, 2017, in our opinion, to the best of our knowledge and according to information and explanations given to us, the remuneration paid by the Group to its directors is within the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
- According to the information and explanations given to us and based on the CARO reports
 issued by us for the Company and its subsidiary are included in the consolidated financial
 statements of the Company to which reporting under CARO is applicable, we report that
 there are no Qualifications/adverse remarks.

ASSO

For M S K A & Associates Chartered Accountants ICAI Firm Registration No. 105047W

Pradeep Mysore Suresh

Partner

Membership No. 216181 UDIN: 22216181AUHLDJ4715

Place: Bengaluru

Date: September 23, 2022

MSKA & Associates Chartered Accountants

ASSO

SV Tower, No. 27, Floor 4 80 Feet Road, 6th Block, Koramangala, Bengaluru 560095, INDIA Tel: +91 80 6811 1600

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF MEDI ASSIST HEALTHCARE SERVICES LIMITED

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we
 are also responsible for expressing our opinion on whether the company has internal financial
 controls with reference to financial statements in place and the operating effectiveness of
 such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the
 entities or business activities within the Group and its associates and jointly controlled
 entities to express an opinion on the consolidated financial statements. We are responsible
 for the direction, supervision and performance of the audit of the financial statements of
 such entities included in the consolidated financial statements of which we are the
 independent auditors. For the other entities included in the consolidated financial
 statements, which have been audited by other auditors, such other auditors remain
 responsible for the direction, supervision and performance of the audits carried out by them.
 We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

MSKA & Associates

Chartered Accountants

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

ASS

For M S K A & Associates Chartered Accountants ICAI Firm Registration No. 105047W

Pradeep Mysore Suresh

Partner

Membership No. 216181 UDIN: 22216181AUHLDJ4715

Place: Bengaluru

Date: September 23, 2022

MSKA & Associates Chartered Accountants

SV Tower, No. 27, Floor 4 80 Feet Road, 6th Block, Koramangala, Bengaluru 560095, INDIA Tel: +91 80 6811 1600

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF MEDI ASSIST HEALTHCARE SERVICES LIMITED

[Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Medi Assist Healthcare Services Limited on the consolidated Financial Statements for the year ended March 31, 2022]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

Opinion

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2022, we have audited the internal financial controls with reference to consolidated financial statements of Medi Assist Healthcare Services Limited (hereinafter referred to as "the Holding Company") and its subsidiary companies which are incorporated in India, as of that date.

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company and its subsidiary companies which are incorporated in India, have, in all material respects, an adequate internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2022, based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("the ICAI").

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company and its subsidiary companies which are incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding company and its subsidiary companies which are incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating

MSKA & Associates Chartered Accountants

effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding company and its subsidiary companies which are incorporated in India.

Meaning of Internal Financial Controls with Reference to Consolidated Financial Statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

ASSO

For M S K A & Associates Chartered Accountants

ICAI Firm Registration No. 105047W

Pradeep Mysore Suresh

Partner

Membership No. 216181 UDIN: 22216181AUHLDJ4715

Place: Bengaluru

Date: September 23, 2022

(All amounts are in Indian Rupees in millions, unless otherwise stated)

| Particulars | Notes | As at 31 March 2022 | As at 31 March 2021 |
|--|--------|------------------------|------------------------|
| ASSETS | | | |
| Non-current assets | | | |
| Property, plant and equipment | 4 | 212.49 | 291.14 |
| Right-of-use assets | 5 (a) | 200.88 | 268.47 |
| Goodwill | 6 | 409.80 | 409.80 |
| Other intangible assets | 7 | 163.81 | 223.47 |
| Intangible assets under development | 7 | 64.61 | 6.94 |
| Financial assets | 8 | | |
| Investments | 8(a) | 69.39 | 74.72 |
| Other financial assets | 8(b) | 34.05 | 42.99 |
| Non-Current tax assets (net) | 9 | 492.47 | 303.12 |
| Deferred tax assets (net) | 10 | 95.20 | 106.42 |
| Other non-current assets | 11 | 6.56 | 8.76 |
| Total non-current assets | | 1,749.26 | 1,735.83 |
| Current assets | | | |
| Financial assets | 12 | | |
| Investments | 12 (a) | 1,945.04 | 1,030.89 |
| Trade receivables | 12 (b) | 1,187.70 | 1,210.80 |
| Cash and cash equivalents | 12 (c) | 145.95 | 633.89 |
| Bank balances other than cash and cash equivalents | 12 (d) | 479.38 | 513.45 |
| Other financial assets | 12 (e) | 249.11 | 192.56 |
| Other current assets | 13 | 265.86 | 123.16 |
| Total current assets | | 4,273.04 | 3,704.75 |
| Non-current assets held for sale | 44 | - | 12.44 |
| Total Assets | | 6,022.30 | 5,453.02 |
| EQUITY AND LIABILITIES | | A8 | |
| EQUITY | | | |
| Equity share capital | 14 | 344.30 | 0.37 |
| Other equity | 15 | 3,026.99 | 2,903.56 |
| Total equity attributable to owners of the Company | | 3,371.29 | 2,903.93 |
| Non-controlling interests | | 21.57 | 21.57 |
| Total equity | | 3,392.86 | 2,925.50 |
| LIABILITIES | | | |
| Non-current liabilities | | | |
| Financial liabilities | | | |
| Lease liabilities | 5 (b) | 175.20 | 256.76 |
| Provisions | 16 | 112.21 | 85.56 |
| Total non-current liabilities | | 287.41 | 342.32 |
| Current liabilities | | | |
| Financial liabilities | | | |
| Lease liabilities | 5 (b) | 99.58 | 96.24 |
| Trade payables | 17 (a) | | |
| total outstanding dues of micro enterprises and small enterprises | | 32.32 | 31.11 |
| total outstanding dues to creditors other than micro enterprises and small enterprises | | 257.88 | 303.77 |
| Other financial liabilities | 17 (b) | 91.55 | 173.72 |
| Contract liabilities | | 1,536.96 | 1,221.96 |
| Other current liabilities | 18 | 257.52 | 224.80 |
| rovisions | 19 | 66.22 | 52.10 |
| Current tax liabilities (net) | 20 | - | 81.50 |
| Total current liabilities | | 2,342.03 | 2,185.20 |
| Total liabilities | | 2,629.44 | 2,527.52 |
| Total Equity and Liabilities | | 6,022.30 | 5,453.02 |
| | | | |

The notes referred to above form an integral part of these consolidated financial statements.

ASSO

red Acco

As per our report of even date attached.

for MSKA & Associates Chartered Accountants

Firm's Registration Number: 105047W

Pradeep Lysore Suresh Partner

Membership Number: 216181

for and on behalf of the Board of Directors of Medi Assist Healthcare Services Limited

CIN:U74900KA2000PLC027229

Dr. Vikram Jit Singh Chhatwal Chairman and Whole Time Director DIN: 01606329

Mathew George

Chief Financial Officer

Place: Bengaluru Date: 23 September 2022

Satish Gidugu Whole Time Director and CEO

DIN: 06643677

Megha Matoo

Chief Compliance Officer and Company Secretary

ealthcar

ICSI Membership No: F-10665

Place: Bengaluru Date: 23 September 2022

Place: Bengaluru Date: 23 September 2022

Consolidated Statement of Profit and Loss for the year ended 31 March 2022

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

| Particulars | Notes | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------|-------------------------------------|-------------------------------------|
| Continuing operations | | | |
| Income | | | |
| Revenue from operations | 21 | 3,938.10 | 3,227.41 |
| Other income | 22 | 182.47 | 225.48 |
| Total income | | 4,120.57 | 3,452.89 |
| Expenses | | | |
| Employee benefits expense | 23 | 1,556.79 | 1,432.64 |
| Finance costs | 24 | 29.50 | 57.26 |
| Depreciation and amortisation expenses | 25 | 284.08 | 315.19 |
| Other expenses | 26 | 1,469.44 | 1,037.39 |
| Total expenses | | 3,339.81 | 2,842.48 |
| Profit before exceptional items and tax for the year | | | |
| Exceptional items | | (26.11) | |
| Profit before tax | | 806.87 | 610.41 |
| Income tax expense: | | | |
| Current tax | 36 | 153.27 | 285.40 |
| Deferred tax (credit)/ charge | 35 | 18.93 | |
| petersed and ferently emaile | 33 | 172.20 | (55.05) 230.35 |
| | | | |
| Profit after tax for the year from continuing operations | | 634,67 | 380.06 |
| Discontinued operations | 37 | | |
| Profit/ loss for the year from discontinued operations | | 10.04 | (150.54) |
| Tax credit from discontinued operations | | (2.53) | 33.23 |
| Profit/loss for the year from discontinued operations (net of taxes) | | 7.51 | (117.31) |
| Profit after tax for the year | | 642.18 | 262.75 |
| Other comprehensive Income | | | |
| Items that will not be reclassified to statement of profit and loss | | | |
| Re-measurement of defined benefit (assets)/ liabilities | | (28.06) | /6 OT) |
| Fair value changes in equity instrument through other comprehensive income | | 7 (11) | (5.87) |
| Income tax relating to items that will not be reclassified to statement of profit and loss | | (5.34) | 13.93 |
| Fotal other comprehensive income for the year, net of income tax | | 7.68 | (3.95) |
| | | | |
| Total comprehensive income for the year | | 616.46 | 266.86 |
| Earnings per share for continuing operation | 28 | | |
| [Face value of Rs. 5 per share (31 March 2021: Rs. 5 per share)] | 20 | | |
| Basic | | 9.22 | *** |
| Diluted | | 9.14 | 5.67 5.62 |
| Earnings per share for discontinued operation | 28 | | |
| Face value of Rs. 5 per share (31 March 2021; Rs. 5 per share)] | 40 | | |
| Basic | | 1000 | 22 200 |
| Diluted | | 0.11 0.11 | (1.75) |
| Compact nor share for continuing and discontinued execution | 26 | 0.3000 | 2(-) |
| Earnings per share for continuing and discontinued operation Face value of Rs. 5 per share (31 March 2021: Rs. 5 per share)] | 28 | | |
| | | 5225 | 327525 |
| Basic | | 9.33 | 3.92 |
| Diluted | | 9.25 | 3.88 |

The notes referred to above form an integral part of these consolidated financial statements.

ASSO

As per our report of even date attached

for MSKA& Associates

Chartered Accountants

Firm's Registration Number: 105047W

Pradeep Mysore Suresh

Partner Membership Number: 216181 Dr. Vikram Jit Singh Chhatwal Chairman and Whole Time Director

CIN:U74900KA2000PLC027229

for and on behalf of the Board of Directors of

Medi Assist Healthcare Services Limited

DIN: 01606329

Satish Oldugu Whole Time Director and CEO

DIN: 06643677

Ch

Mathew George Chief Financial Officer Megha Matoo

Chief Compliance Officer and Company Secretary ICSI Membership No: F-10665

althca

Place: Bengaluru

Date: 23 September 2022

Place: Bengaluru Date: 23 September 2022

Place: Bengaluru Date: 23 September 2022

Consolidated Statement of Cash Flows for the year ended 31 March 2022 (All amounts are in Indian Rupees in millions, unless otherwise stated)

| Particulars | For the year ended 31 March 2022 | For the year ender 31 March 202 |
|---|-------------------------------------|------------------------------------|
| Cash flows from operating activities | | |
| Profit before tax for the year from continuing operations | 806.87 | 610.41 |
| Profit/ (Loss) before tax for the year from discontinued operations | 10.04 | (150.54 |
| Adjustments: | | |
| Depreciation and amortisation expenses | 284.08 | 315.19 |
| Allowance for expected credit losses on trade receivables and unbilled receivables | 120.71 | 273.61 |
| Provision for doubtful deposits | - | 0.55 |
| Provision for doubtful advances | 0.55 | 3.34 |
| Creditors/ Provision no longer required written back | (11.52) | (20.61 |
| Rent concession | - | (26.50 |
| Employee stock option expense | 23.04 | |
| Finance costs | 28.71 | 47.60 |
| Profit on sale of investments in mutual funds | (12.35) | (11.72 |
| Profit on sale of non-current investments | | (46.42 |
| Interest income | (31.29) | (78.30 |
| Net gain on financial assets measured at fair value through profit and loss | (46.34) | (8.94 |
| Loss on transfer of property, plant and equipment | (60.34) | |
| Operating cash flows before working capital changes | 1,112.16 | 907.67 |
| Working capital adjustments: | 5.50000000 | |
| (Decrease) in trade payables | (33.14) | (33.77 |
| Increase/ (Decrease) in other liabilities | 262.92 | (151.79) |
| Increase in provisions | 11.71 | 11.16 |
| Decrease in trade receivables | (97.61) | (47.16 |
| Decrease/ (Increase) in other assets | (185.36) | 383.73 |
| Cash generated from operations | 1,070.67 | 1,069.84 |
| Income taxes refund/ (paid), net | (426.68) | 324.58 |
| Net cash flows generated from operating activities (A) | 643.99 | 1,394.42 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment, other intangible assets including capital advances | (60.06) | (119.67) |
| Intangible assets under development (refer note 7) | (57.67) | (12.86) |
| Proceeds from sale of non-current investments | (2111.) | 138.48 |
| Purchase of non-current investments | | (0.50) |
| Sale of property, plant and equipment, other intangible assets including capital advances | 90.27 | (0.50) |
| (Purchase of)/ Proceeds from sale of current investments, (net) | (855.46) | (443.41) |
| Investment in fixed deposit accounts | (8.65) | (242.02) |
| Proceeds from maturity of fixed deposits | 34.07 | (2-12-02) |
| Interest received | 28.51 | 71.98 |
| Net cash flows used in investing activities (B) | (828.99) | (608.00) |
| Cash flows from financing activities | | |
| Repayment of non-convertible debentures | | (2.00) |
| Repayment of lease liabilities (Refer Note 5(b) A) | (129.59) | |
| Dividend paid | | (90.15) |
| Finance costs paid | (172.15) | · /6.22) |
| Net cash flows used in financing activities (C) | (302.94) | (5.77) |
| Net increase/ (decrease) in cash and cash equivalents | (497.04) | 000000000 |
| Cash and cash equivalents at the beginning of the year | (487.94) 633.89 | 688.45 |
| Cash and cash equivalents at the end of the year | 145.95 | (54.56) 633.89 |
| Component of cash and cash equivalents (Refer Note 12 (c)) | | |
| Balances with banks | | |
| - In current accounts | 145.69 | 633.06 |
| Deposits with original maturity of less than three months | • | 0.58 |
| Cash on hand | 0.26 | 0.25 |
| Total cash and cash equivalents | 145.95 | 633.89 |



(This space is intentionally left blank)





Consolidated Statement of Cash Flows for the year ended 31 March 2022 (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

Reconciliation of financial liabilities forming part of financing activities in accordance with Ind AS 7:

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-------------------------------------|-------------------------------------|
| (a) Lease liabilities (Non-current and current): | 202227 | 7,000 |
| Opening balance | 353.00 | 427.48 |
| (i) Non-cash movements in financing activities | | |
| Additions | 23.86 | 9.13 |
| Deletions | | |
| Interest expense for the year | 27.51 | 33.04 |
| Rent concession | | (26.50) |
| (ii) Cash movements in financing activities | | |
| Repayment of lease liabilities | (129.57) | (90.15) |
| Lease liability outstanding | | |
| TO DESCRIPTION OF MAINTAINS CONTROLLED | 274.80 | 353.00 |

The above cash flow statement has been prepared under the indirect method as set out in Ind AS 7 Statement of Cash Flows u/s 133 of Companies Act, 2013 ('Act') read with Rule 4 of the Companies (Indian Accounting Standards) Rules 2015 and the relevant provisions of the Act.

The notes referred to above form an integral part of these consolidated financial statements.

ASSO

As per our report of even date attached

for MSKA & Associates

Chartered Accountants

Firm's Registration Number: 105047W

Pradeep Mysore Suresh

Partner

Place: Bengaluru

Date: 23 September 2022

Membership Number: 216181

for and on behalf of the Board of Directors of

Medi Assist Healthcare Services Limited CIN:U74900KA2000PLC027229

CIN.O/4900KA2000FDC02/225

Dr. Vikram Jit Singh Chhatwal

Chairman and Whole Time Director

DIN: 01606329

Mathew George

Chief Financial Officer

Place: Bengaluru

Date: 23 September 2022

Satish Gidugu

Whole Time Director and CEO

DIN: 06643677

Megha Matoo

Chief Compliance Officer and Company Secretary

altho

ICSI Membership No: F-10665

Place: Bengaluru

Date: 23 September 2022

Medi Assist Healthcare Services Limited
Consolidated Statement of Changes in Equity for the year ended 31 March 2022
(All amounts are in Indian Ropers in millions except share data and per share data, unless otherwise stated)

A. Equity share capital*

| Particulars | N | As at 31 Mar | arch 2022 | As at 31 March 20 | rch 2021 |
|--------------------------------------|-------|------------------|-----------|-------------------|----------|
| | CHANT | Number of shares | Amount | Number of shares | Amount |
| Balance at the beginning of the year | (a) | 37,181 | 0.37 | 36,082 | 0.36 |
| Shares issued during the year | (8) | 68,822,031 | 343.91 | 1,099 | 10.0 |
| Balance at the end of the year | | 68,859,212 | 344.28 | 37,181 | 0.37 |

(a) Refer Note 14(a).

B. Other equity

| Particulars | Notes | | | Re | Reserve and Surplus | | | | Items of Other Comprehensive Income (OCI) | Total attributable to owners of the | Non-controlling | Total |
|---|-------|----------------------------------|--------------------|----------|---------------------|---------------------------------|-----------------------------|---------------|---|--|-------------------|----------|
| | | Employee stock option reserve | Securities premium | Retained | General reserve | Debenture redemption reserve | Demerger deficit balance | Other equity* | Equity instrument through | company | Illieresi (NCI) | |
| Restated balance as at 1 April 2020 | | 55.75 | 08'995 | 1,583.17 | • | 1.36 | (370.18) | 369.85 | (63.08) | 2,113.67 | 21.57 | 2,135.24 |
| Profit after tax for the year from contaming operations | | ř | * | 380.06 | | 9 | × | , | | 380.06 | , | 380.08 |
| (Loss) after tax for the year from discontinued operations. | | | | (117.31) | 3 | 9 | | | 24 | (117.31) | | (117.31) |
| Remeasurements of defined benefit liability (asset) | | * | | (4.39) | • | | ė | 2 | * | (4.39) | * | (4.39) |
| Other comprehensive loss, net of income tax | | 4 | 4 | * | | | | 4 | 8.55 | 8.55 | | 8.55 |
| Total Comprehensive income for the year | | * | | 258.36 | | | | | 8.55 | 266.91 | | 166.91 |
| Transactions recorded directly in equity: Premium received on issue of equity shares | (8) | • | \$22.99 | | | × | × | 4 | ٠ | 522.99 | | \$22.99 |
| Transfer of debenture redemption reserve to general reserve | | | 06 | | 1.36 | (1.36) | | | | | | |
| Bainnee as at 31 March 2021 | | 55.75 | 1,089.79 | 1,811,53 | 1.36 | | (370.18) | 369.85 | (54.53) | 2,903.57 | 21.57 | 2,925.14 |
| Balance as at 1 April 2021 | | 56.75 | 1,089.79 | 1,811.53 | 1.36 | , | (370.18) | 369.85 | (54.53) | 2,903.57 | 21.57 | 2.925.14 |
| Profs after tax for the year from continuing operations | | | | 634.67 | | | | | | | , | 634.67 |
| Profit after tax for the year from discontinued operations | | | * | 7.51 | ٠ | | 94 | | | 7.51 | - 54 | 7.51 |
| Remeasurements of defined benefit liability/ (asset) | | 35 | | (21.00) | ٠ | | | F | | (21.00) | , | (21.00) |
| Other comprehensive income, net of income tax | | | * | | | | | | (4.72) | (4.72) | • | (4,72) |
| Total Comprehensive income for the year | | 4 | | 621,18 | | | | | (4.72) | 9 | | 616.46 |
| Transactions recorded directly in equity: Dividend paid | | | * | (172.15) | | * | | | | (172.15) | 3 | 072.150 |
| Employee stock option compensation cost (net) | | 23.04 | .90 | ٠ | • | | | | | 23.04 | 33% | 23.04 |
| Utilisation of Securities Premium on issue of bonus shares | | | (343.92) | | - | | 1000000 | 1000 | | (343.92) | * | (343.92) |
| Balance as at 31 March 2022 | | 78.79 | 745,87 | 2,260.56 | 1.36 | | (370,18) | 369.85 | (59.25) | | 15:12 | 3.048.57 |

(a) Refer Note 15(i).

* Other Equity (Refer Note 15 (iv)).

** Equity instrument through OCI:
The Group has elected to recognize the changes in fair value of certain investments in equity securities in other comprehensive income. These changes are accumulated within PVOCI equity investments within equity. The Group transfers amount to relained earnings when the relevant equity securities are de-recognised.

*** The employue stock option reserve of MoS Asist Insurance TPA Private Limited (MATPA), a wholly owned subsidiary of the Company, represents the ESOP's granted to counterparty not forming part of the consolidated reporting entity are classified and presented as NCI. These ESOP's are not exercised as at balance short date. Hence, no profit is astributable to NCI.

The notes referred to above form an integral part of these consolidated financial statements.

As per our report of even date.

Firm's Registration Number, 105047W for M S K A & Associates Chartered Accountance

Pradeep Mysore Suresh

SW + Ch

ES + SIG

Place: Bengalum Date: 23 September 2022

Membership Number: 216181

for and on behalf of the Board of Directors of Medi Assist Healthcare Services Limited Dr. Vildage Jit Singh Chhatwal Changan and Whole Time Director CIN:U749008CA2000PLC027229

Place: Bengaluna Date: 23 September 2022 DIN: 01606329

Mitch Gldugu Whole Time Director and CEO DIN: 06643677

Place: Bengaluru Date: 23 September 2022

Mathew George Chief Financial Officer

Place: Bengaluru Date: 23 September 2022

Megha Matoo

ervices

Chief Compliance Officer and Company Secretary ICSI Membership No. F-10665

Place: Bengaluru Date: 23 September 2022

1 Reporting entity

Medi Assist Healthcare Services Limited ("the Company" or "Parent"), was incorporated on 7 June 2000 under the provisions of Companies Act, 1956. The Company received order from the Registrar of Companies with fresh certificate of incorporation upon conversion from Private Company to Public Company with effect from 20 March 2018. The Company's registered office is Medi Assist Healthcare Services Limited, Tower D, 4th Floor, IBC Knowledge Park, 4/1, Bannerghatta Road, Bengaluru 560 029. The business operations of the Company are carried out at various cities in India.

The Company, and its subsidiary i.e. Medi Assist Insurance TPA Private Limited, ("MATPA") (collectively the "Group"), is mainly engaged in the business of Third Party Administration (TPA) services provided by the subsidiary. The Group has signed up contracts with several general and health insurance companies to manage the requirements of their policyholders, as well as with healthcare providers (such as hospitals) to enable a network for policyholders to avail of cashless treatment at pre-negotiated tariffs. The Group also provides business support services, health management services, consultancy services and contact centre support and other allied services pertaining to the healthcare and health insurance sector. The Group primarily derives its income in the form of TPA fees from insurance companies expressed either as a percentage of the insurance premium paid by the insurance to the insurance company or as a fixed price per member/ family. The Group also derives income from pre-policy check ups and other allied services provided to insurance companies, and for policy administration services rendered to Governments to enable public health schemes.

Pursuant to the Scheme of Arrangement, duly sanctioned by the National Company Law Tribunal (NCLT), vide Order dated 4 November 2020, with effect from the Appointed Date i.e. 1 September 2019, the CH Business of the Company has demerged into M/s. Mandala Wellness Private Limited ('MWPL'), Accordingly, the Group has disclosed the discontinuation of CH business as discontinued operations as per the requirement of Ind AS 105 'Non current asset held for sale and Discontinued operation', the details of which are stated in Refer Note 37 (i).

The Board of Directors of the Company vide resolution dated 30 December 2020 has approved the discontinuation of the business pertaining to card processing which are mainly generating revenue from Government contracts. Accordingly, the Group has disclosed the discontinuation of card processing business as discontinued operations as per the requirement of Ind AS 105 \(^1\) Non current asset held for sale and Discontinued operation, the details of which are stated in Refer Note 37 (ii). The Group has re-represented the comparative information due to the discontinued operations.

The Consolidated Financial Statements comprises the financial information of the member of the Group as under:

| Kar asangsan | Country of | % of Inte | rest |
|---|---------------|------------------------|------------------------|
| Name of subsidiary | incorporation | As at 31 March 2022 | As at 31 March 2021 |
| Medi Assist Insurance TPA Private Limited | India | 99.99 | 99.99 |

2 Basis of accounting and preparation

A Statement of compliance:

The Consolidated Financial Statements has been prepared in accordance with Indian Accounting Standards ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013. (the 'Act') and other relevant provisions of the Act as amended from time to time.

These Consolidated Financial Statements have been prepared for the Group as a going concern on the basis of relevant Ind AS that are effective as at 31 March 2022. These Consolidated Financial Statements have been approved by the Board of Directors on 23 September 2022.

B Functional and presentation currency

These Consolidated Financial Statements are presented in Indian Rupces, which is the Group functional currency. All amounts have been rounded to the nearest million, upto two places of decimal, unless otherwise stated.

C Basis of measurement

The Consolidated Financial Statements have been prepared under the historical cost basis, except for the following:

| Items | Measurement basis |
|--|--|
| Financial assets and liabilities (including derivatives instruments) | Fair value |
| Share based payment at grant date | Fair value |
| Defined benefit and other long-term employee benefits obligations | Present value of defined benefit obligations |

D Use of estimates and judgements

In preparing these Consolidated Financial Statements, management has made estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the year. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the year in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

Judgement, estimates and assumptions are required in particular for:

(a) Determination of the estimated useful lives:

Useful lives of property, plant and equipment are based on the life prescribed in Schedule II of the Companies Act, 2013. In cases, where the useful lives are different from that prescribed in Schedule II and in case of intangible assets, these are estimated by management taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers' warranties and maintenance support.

(b) Recognition of deferred tax assets:

Deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases, and unutilized business loss and depreciation carry-forwards and tax credits. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carry-forwards and unused tax credits could be utilized.

(c) Recognition and measurement of defined benefit obligations:

The obligation arising from defined benefit plan is determined on the basis of actuarial assumptions. Key actuarial assumptions include discount rate, trends in salary escalation, actuarial rates and life expectancy. The discount rate is determined by reference to market yields at the end of the reporting period on government bonds. The period to maturity of the underlying bonds correspond to the probable maturity of the post-employment benefit obligations. Due to complexities involved in the valuation and its long term nature, defined benefit obligation is sensitive to changes in these assumptions. All assumptions are reviewed at each reporting period.

ASSOC

(d) Fair valuation of employee share options:

The fair valuation of the employee share options is based on the Black-Scholes Model use expected dividends and discount rate, under option pricing model. key assumptions made with respect to expected volatility includes share price,



2 Basis of accounting and preparation (continued)

D Use of estimates and judgements (continued)

(e) Impairment testing:

Property, plant and equipment, goodwill, intangible assets and other assets are tested for impairment at least annually and when event occur or changes in circumstances indicate that the recoverable amount of the asset or cash generating units to which these pertain is less than its carrying value. The recoverable amount of cash generating units is higher of value-in-use and fair value less cost to dispose. The calculation of value in use of a cash generating unit involves use of significant estimates and assumptions which includes turnover and earnings multiples, growth rates and net margins used to calculate projected future cash flows, risk-adjusted discount rate, future economic and market conditions.

(f) Business combination:

In accounting for business combinations, judgment is required in identifying whether an identifiable intangible asset is to be recorded separately from goodwill. Additionally, estimating the acquisition date fair value of the identifiable assets (including useful life estimates), liabilities acquired and contingent consideration assumed involves management judgment. These measurements are based on information available at the acquisition date and are based on expectations and assumptions that have been deemed reasonable by the management. Changes in these judgments, estimates, and assumptions can materially affect the results of operations.

(g) Leases

The Group evaluates if an arrangement qualifies to be a lease based on the requirements of the relevant standard, Identification of a lease requires significant management judgment. Computation of the lease liabilities and right-to-use assets requires management to estimate the lease term (including anticipated renewals) and the applicable discount rate. Management estimates the lease term based on past practices and reasonably estimated/ anticipated future events. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristic.

(h) Expected credit losses on financial assets:

The impairment provisions of financial assets are based on assumptions about risk of default and expected timing of collection. The Group uses judgment in making these assumptions and selecting the inputs to the impairment calculation, based on the Group past history, customer's creditworthiness, existing market conditions as well as forward looking estimates at the end of each reporting years.

E Measurement of fair values

The Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group has an established control framework with respect to the measurement of fair values, The Group regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of lad AS, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring the fair value of a financial asset or a financial liability, the Group uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in the following notes:

- Note 31: Employee Stock Option Scheme.
- Note 32: Financial Instruments

F Current and non-current classification

The Group presents assets and liabilities in the Consolidated Balance sheet based on current/non-current classification.

An asset is classified as current when it satisfies any of the following criteria:

- it is expected to be realized in, or is intended for sale or consumption in, the Group's normal operating cycle.
- it is held primarily for the purpose of being traded;
- it is expected to be realized within 12 months after the reporting date; or
- it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

A liability is classified as current when it satisfies any of the following criteria:

- it is expected to be settled in the Group's normal operating cycle;
- it is held primarily for the purpose of being traded;
- it is due to be settled within 12 months after the reporting date; or
- the Group does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current assets/ liabilities include current portion of non-current financial assets/ liabilities respectively.

All other assets/ liabilities are classified as non-current. Deferred tax assets and liabilities (if any) are classified as non-current assets and liabilities.

Operating cycle

Based on the nature of the operations and the time between the acquisition of assets for processing and their realization in cash or cash equivalents, the Group has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.



(This space is intentionally left blank)





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

3 Significant accounting policies

The accounting policies set out below have been applied consistently throughout the period presented in these Consolidated Financial Statements, and have been applied consistently by Group entities:

a. Basis of consolidation

Subsidiary:

The Company determines the basis of control in line with the requirements of Ind AS 110. Consolidated Financial Statements.

Subsidiary is entity controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiary are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases,

The Group combines the financial statements of the parent and its subsidiary line by line adding together like items of assets, liabilities, equity, income and expense. Intercompany transactions, balances and unrealized gains on transactions between Group entities are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of transferred asset. Accounting policies of subsidiary have been changed where necessary to ensure consistency with the policies adopted.

Non-controlling interests ("NCI") in the results and equity of subsidiary are shown separately in the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss and Consolidated Statement of Changes in Equity respectively. Also the employee stock option reserve of the subsidiary Company represents the ESOP's granted to counterparty (employees of the Group) not forming part of the consolidated reporting entity are classified and presented as NCI.

All intra-Group balances, transactions, income and expenses are eliminated in full on consolidation.

The accounting policies of subsidiaries have been changed when necessary to align them with the policies adopted by the Group.

b. Financial instruments

(i) Recognition and initial measurement

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments also include derivative contracts such as foreign currency forward contracts.

Financial instruments also covers contracts to buy or sell a non-financial item that can be settled net in cash or another financial instrument, or by exchanging financial instruments, as if the contracts were financial instruments, with the exception of contracts that were entered into and continue to be held for the purpose of the receipt or delivery of a non-financial item in accordance with the entity's expected purchase, sale or usage requirements.

Financial assets and financial liabilities are recognized when the Group becomes a party to the contractual provisions of the instruments.

Recognition and initial measurement - financial assets and financial liabilities:

A financial asset (except for trade receivables and contract assets) or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in the Consolidated Statement of Profit and Loss.

ii. Finance income consists of interest income on funds invested, dividend income and gains on the disposal of FVTPL financial assets. Interest income is recognized as it accrues in the Consolidated Statement of Profit and Loss, using the effective interest method.

Dividend income is recognized in the Consolidated Statement of Profit and Loss on the date that the Group's right to receive payment is established, it is probable that the economic benefits associated with the dividend will flow to the Group, and the amount of dividend can be measured reliably.

iii. Finance expenses consist of interest expense on loans and borrowings and financial liabilities. The costs of these are recognized in the Consolidated Statement of Profit and Loss using the effective interest method.

Financial assets

The Group classifies financial assets as measured at amortized cost, fair value through other comprehensive income ("FVOCI") or fair value through profit and loss ("FVTPL") on the basis of following

- the entity's business model for managing the financial assets and
- the contractual cash flow characteristics of the financial asset.

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Group changes its business model for managing financial assets.

Amortized cost

A financial asset is classified and measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Fair value through other comprehensive income ("FVOCI"):

A financial asset is classified and measured at FVOCI if both of the following conditions are met:

- the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI equity investment). This election is made on an investment by investment basis.

Fair value through profit and loss ("FVTPL")

A financial asset is classified and measured at FVTPL unless it is measured at amortized cost or at FVOCI. This includes all derivative financial assets. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Group makes an assessment of the objective of the business model in which a financial asset is held at investment level because this reflects the best way the business is managed and information is provided to management. The information considered includes

- the stated policies and objectives for each of such investments and the operation of those policies in practice.
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity,

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Group's continuing recognition of the

d at FVTPL Financial assets that are held for trading or are managed and whose performance is evaluated on



3 Significant accounting policies (continued)

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest:

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Group considers the contractual terms of the instrument. This includes assessing whether the financial asset contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Group considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Group's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

Financial assets: Subsequent measurement and gains and losses

| Financial assets at FVTPL | These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in the Consolidated Statement of Profit and Loss. |
|------------------------------------|--|
| Financial assets at amortised cost | These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in Consolidated Statement of Profit and Loss. Any gain or loss on derecognition is recognised in Consolidated Statement of Profit and Loss. |
| Equity investments at FVOCI | These assets are subsequently measured at fair value. Dividends are recognised as income in Consolidated Statement of Profit and Loss unless the dividence clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OC1 and are not reclassified to Consolidated Statement of Profit and Loss. |

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in Consolidated Statement of Profit and Loss

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in Consolidated Statement of Profit and Loss. Any gain or loss on derecognised in Consolidated Statement of Profit and Loss.

(iii) Derecognition

Financial assets

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

Financial liabilities

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in Consolidated Statement of Profit and Loss.

(iv) Offsetting financial instruments:

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

c. Foreign currency transactions and balances

Transactions in foreign currencies are translated into the respective functional currency of the Group at the exchange rates at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Foreign currency differences are generally recognised in the Consolidated Statement of Profit and Loss.



(This space is intentionally left blank)





3 Significant accounting policies (continued)

d. Cash and cash equivalents

Cash and cash equivalents in the Consolidated Balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the Consolidate Statement of Cash Flows, cash and cash equivalents consist of cash excluding restricted cash balance and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Group's cash management.

e. Cash flow statemen

Cash flows are reported using indirect method, whereby net profits before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Group are segregated.

f. Earnings per share

The basic earnings per share ("EPS") is computed by dividing the net profit/ (loss) after tax for the years attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

The number of shares used in computing diluted earnings per share comprises the weighted average number of shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date. In computing dilutive earning per share, only potential equity shares that are dilutive i.e. which reduces earnings per share or increases loss per share are included.

Basic EPS is calculated by dividing the profit for the year attributable to equity holders of the Group by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, stock split, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources.

Diluted EPS adjust the figures used in the determination of basic EPS to consider:

- . The after-income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- . The weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

g. Revenue recognition

i. Revenue is recognized upon transferring control of promised services to customers in an amount that reflects that consideration we expect to receive in exchange for those services.

The Group derives revenue from rendering Third Party Administration (TPA) services is measured either as a percentage of insurance premium or amount per member/ family covered under the policy depending on the terms of the contract entered into with insurance companies and government agencies. Such amounts are recognized as revenue on a pro-rata basis during the period of the underlying insurance policy. Performance obligations while rendering services are satisfied over time, as and when the services are rendered since the customer simultaneously receives and consumes the benefits provided by the Group.

The Group derives revenue from rendering healthcare management services in accordance with the terms of the relevant service agreement entered with customers.

The Group derives revenue from rendering business support services in accordance with the terms of the relevant service agreement entered with customers, being performance obligations are satisfied over the contract period as the Group's efforts or inputs are expanded evenly throughout the contract period.

Revenue from card processing income are recognised at point in time as and when the related services are rendered.

Revenue from licenses where the customers obtains "right to access" is recognized over the access period...

The Group presents revenues net of indirect taxes in its Consolidated Statement of Profit and Loss.

Revenue in excess of invoicing are classified as unbilled receivables (under trade receivables) where related performance obligation are rendered and right to consideration is unconditional. Invoicing in excess of revenues are classified as contract liabilities.

A contract liability is the obligation to transfer of services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Group transfers of services to the customer, a contract liabilities are recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group fulfils the performance obligation under the contract..

h. Property, plant and equipment

Recognition and measurement:

Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses, if any. The cost of an item of property, plant and equipment comprises:

- a) its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates.
- b) any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.
- c) the initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located, the obligation for which an entity incurs either when the item is acquired or as a consequence of having used the item during a particular period for purposes other than to produce inventories during that year.

An item of property, plant and equipment is eliminated from the financial statements on disposal or when no further benefit is expected from its use and disposal. Any gain or loss on disposal of an item of property, plant and equipment is recognised in Consolidated Statement of Profit and Loss.

An item of property, plant and equipment is eliminated from the financial statements on disposal or when no further benefit is expected from its use and disposal. Any gain or loss on disposal of an item of property, plant and equipment is recognised in Consolidated Statement of Profit and Loss.

Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital work-in-progress.

Depreciation

Depreciation on property, plant and equipment is provided on straight-line method over the useful lives determined based on internal assessment by the Management which in certain instances are different from those prescribed under Part C of Schedule II of the Companies Act, 2013 in order to reflect actual usage of the assets. The Group estimates the useful lives for property, plant and equipment as follows:

| Asset categories | Useful life in years |
|--|----------------------|
| Furniture and fixtures | 10 |
| Air conditioners | 10 |
| Computer equipment's - end user devices | 3 |
| Motor car | 10 |
| Computer equipment's - servers and network | 6 |
| Electrical equipment's | 10 |
| Office equipment | 5 |





Depreciation is provided on a pro-rata basis i.e. from the date on which asset is ready for use and the depreciation charge for the year is recognised in Consolidated Statement of Profit and Loss.

Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

3 Significant accounting policies (continued)

i. Intangible assets

(i) Recognition and measurement

Acquired intangible assets

Intangible assets are recognized when it is probable that the future economic benefits that are attributable to the assets will flow to the Group and the cost of the asset can be measured reliably. Intangible assets are stated at cost less accumulated amortization and impairment losses, if any.

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors such as the stability of the industry and known technological required to obtain the expected future cash flows from the asset.

Internally generated intangible assets

Expenditure on research activities, undertaken with prospect of gaining new scientific or technical knowledge and understanding, is recognised in the Consolidated Statement of Profit and Loss as incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and capitalised borrowing costs. Other development expenditure is recognised in Consolidated Statement of Profit and Loss as incurred.

Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in Consolidated Statement of Profit and Loss as incurred.

Amortisation

Amortisation is calculated based on the cost of the asset, less its residual value.

Amortisation is recognised in Consolidated Statement of Profit and Loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use. Management believes that period of amortisation is representative of the period over which the Group expects to derive economic benefits from the use of the assets.

Amortisation methods and useful lives are reviewed periodically including at each financial years end. Amortisation on additions and disposals during the years is provided on proportionate basis. Goodwill is measured at cost less accumulated impairment loss.

The intangible assets are amortised over the estimated useful lives as given below:

| Asset categories | Useful life in years |
|-----------------------|----------------------|
| Software and licenses | 3 |
| Customer contracts | 10 |
| Customer relationship | 8 |

i. Impairment of financial assets

In accordance with Ind AS 109, the Group applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:
a) Financial assets which are measured at amortized cost e.g., loans receivables, deposits and bank balance.

b) Trade receivables (including unbilled receivables) or another financial asset that result from transactions that are within the scope of Ind AS 115.

Loss allowances for trade receivables (including unbilled receivables) is measured at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument. Lifetime expected credit loss is computed based on a provision matrix which takes in to the account risk profiling of customers and historical credit loss experience adjusted for forward looking information. For other financial assets, expected credit loss is measured at the amount equal to twelve months expected credit loss unless there has been a significant increase in credit risk from initial recognition, in which case those are measured at lifetime expected credit loss. In addition the Group base considered credit reports and other credit information for its customers to estimate the probability of default in future and has taken into account estimates of possible effect from the pandemic relating to COVID-19. The Group believes that the carrying amount of allowance for expected credit loss with respect to trade receivables, unbilled receivables and other financial assets is adequate.

Wrise off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write- off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with Group's procedures for the recovery of amount due.

k. Impairment of non-financial assets

Goodwill is tested for impairment at least annually and when events occur or changes in circumstances indicate that the recoverable amount of the cash generating unit is less than its carrying value. The impairment test is performed at the level of cash generating unit or groups of cash-generating units which represent the lowest level at which they are monitored for internal management purposes. Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGU.

The Group assesses long-lived assets such as property, plant, equipment and acquired/ self generated intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be recoverable. If any such indication exists, the Group estimates the recoverable amount of the asset or group of assets.

The recoverable amount of an asset or eash generating unit is the higher of its fair value less cost of disposal (FVLCD) and its value-in-use (VIU). The VIU of long-lived assets is calculated using projected future eash flows. FVLCD of a cash generating unit is computed using turnover and earnings multiples. If the recoverable amount of the asset or the recoverable amount of the asset per long is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the Consolidated Statement of Profit and Loss. If at the reporting date, there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the impairment losses previously recognized are reversed such that the asset is recognized at its recoverable amount but not exceeding written down value which would have been reported if the impairment losses had not been recognized initially. An impairment loss recognized in subsequent periods.



The althour of the street of t

Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

3 Significant accounting policies (continued)

L Lease

Policy applicable with effect from 1 April 2019

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Group as a lessee

The Group's lease asset class primarily consist of leases for buildings. The Group, at the inception of a contract, assesses whether the contract is a lease or not lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset, the Group assesses whether:

- (i) the contract involves the use of an identified asset;
- (ii) the Group has the right to obtain substantially all the economic benefits from use of the asset throughout the period of use; and
- (iii) the Group has the right to direct the use of the asset.

The Group recognises a right-of-use asset and a lease liability at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remensurement of the lease liability. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the Consolidated Statement of Profit and Loss.

The Group measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Group uses incremental borrowing rate. For leases with reasonably similar characteristics, the Group, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease payments, saidual value guarantees, exercise price of a purchase option where the Group is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lesses exercising an option to terminate the lease. The lease liability is subsequently remeasured by increasing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect the lease payments. The Group recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the re-measurement in Consolidated Statement of Profit and Loss.

The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Group recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

Extension and termination options are included in a number of property and equipment leases across the group. These are used to maximise operational flexibility in terms of managing the assets used in the group's operations. The majority of extension and termination options held are exercisable only by the group and not by the respective lessor.

Critical judgements in determining the lease term

In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated).

For leases of office, the following factors are normally the most relevant:

- (a) If there are significant penalties to terminate (or not extend), the group is typically reasonably certain to extend (or not terminate).
- (b) If any leasehold improvements are expected to have a significant remaining value, the group is typically reasonably certain to extend (or not terminate).
- (c) Otherwise, the group considers other factors including historical lease durations and the costs and business disruption required to replace the leased asset. Most extension options in offices leases have not been included in the lease liability, because the group could replace the assets without significant cost or business disruption.

m. Employee benefits

(i) Short-term employee benefits:

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus and exgratia. The undiscounted amount of short-term employee benefits expected to be paid in exchange for employee services is recognized as an expense for the related service rendered by employees.

(ii) Post-employment benefits:

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Group makes specified monthly contributions towards employee provident fund and employees state insurance to a Government administered scheme which is a defined contribution plan. The Group's contribution is recognized as an expense in the Consolidated Statement of Profit and Loss during the period in which the employee renders the related service.

Defined benefit plans

The Group's gratuity benefit scheme is a defined benefit plan. The Group's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value.

The present value of the obligation under such benefit plan is determined by independent qualified actuary using the Projected Unit Credit Method which recognizes each period of service that give rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

The obligation is measured at present values of estimated future cash flows. The discounted rates used for determining the present value are based on the market yields on Government Securities as at the balance sheet dates. The Group classifies the gratuity as current and non-current based on the actuarial valuation report.

Actuarial gains or losses are recognised in Other comprehensive income ('OCI'). Further, the profit or loss does not include an expected return on plan assets. Instead net interest recognised in Consolidated Statement of Profit and Loss is calculated by applying the discount rate used to measure the defined benefit obligation to the net defined benefit liability or asset. The actual return on the plan assets above or below the discount rate is recognised as part of re-measurement of net defined liability or asset through OCI.

Re-measurements comprising actuarial gains or losses and return on plan assets (excluding amounts included in net interest on the net defined benefit liability) are not reclassified to Consolidated Statement of Profit and Loss in subsequent periods.

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in the Consolidated Statement of Profit and Loss as past service cost.

The Group have considered only such changes in legislation which have been enacted upto the balance sheet date for the purpose of determining defined benefit obligation.

Compensated absences

The employees can carry-forward a portion of the unutilised accrued compensated absences and utilise it in future service periods. The Group records an obligation for such compensated absences in the period in which the employee randers the services that increase this entitlement. The obligation is measured by independent qualified actuary using the Projected Unit Credit Method.





3 Significant accounting policies (continued)

m. Employee benefits (continued)

Share-based compensation

The expenses relating to share-based payments in the Consolidated Statement of Profit and Loss using fair value in accordance with Ind AS 102, Share-Based Payment. These Employee Stock Options Scheme ("ESOS") granted are measured by reference to the fair value of the instrument at the date of grant.

The expense is recognized in the Consolidated Statement of Profit and Loss with a corresponding increase to the employee stock option plan reserve, a component of equity. The equity instruments generally vest in a graded manner over the vesting period. The fair value determined at the grant date is expensed over the vesting period of the respective tranches of such grants (accelerated amortization).

When the terms of an equity-settled award are modified, the minimum expense recognised is the expense had the terms had not been modified, if the original terms of the award are met. An additional expense is recognised for any modification that increases the total fair value of the share based payment transaction, or is otherwise beneficial to the employee as measured at the date of modification.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share

Employee stock option reserve of share option granted by MATPA is classified as non-controlling interest in the Consolidated Statements of Changes in Equity.

n. Business combination

In accordance with Ind AS 103, Business combinations, the Group accounts for business combinations after acquisition date using the acquisition method when control is transferred to the group. The cost of an acquisition is measured at the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange. The cost of acquisition also includes the fair value of any contingent consideration and deferred consideration, if any. Any excess of purchase consideration over the fair value of net assets acquired is considered as goodwill. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in OCI and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons for classifying the business combination as resulting in a bargain purchase; otherwise the gain is recognised directly in equity as capital reserve. Transaction costs are expensed as incurred.

The Group accounts for the common control transactions in accordance with the 'pooling of interest' method prescribed under Ind AS 103 - Business Combination for common control transactions and as per the provisions of respective schemes approved by the regulators, where all the assets and hisbilities of transferor companies would be recorded at the book value as at the Appointed date.

o. Taxation

Income tax comprises current and deferred tax. Income tax expense is recognised in the Consolidated Statement of Profit and Loss except to the extent it relates to a business combination, or items directly recognized in equity or in other comprehensive income.

Current income tax

Current tax comprises the expected tax payable or receivable on the taxable income for the period and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting dates.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the assets and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for tuxation purposes. Deferred tax is also recognized in respect of carried forward tax losses and tax credits. Deferred tax is not recognized for:

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor tuxable profit or loss at the time of transaction
- temporary differences related to investments in subsidiaries and associates, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foresecable future.

Deferred tax assets are recognized to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Group recognizes a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realized. Deferred tax assets recognized or unrecognized are reviewed at each reporting date and are recognized/ reduced to the extent that it is probable / no longer probable respectively that the related tax benefit will be realized.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.



(This space is intentionally left blank)





3 Significant accounting policies (continued)

p. Non-current Assets held for sale and discontinued operations

Non-current assets are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use. Such assets are generally measured at the lower of their carrying amount and fair value less costs to sell. Once classified as held-for-sale, intangible assets and property, plant and equipment are no longer amortised or depreciated.

Losses on initial classification as held for sale and subsequent gains and losses on re-measurement are recognised in Consolidated Statement of Profit and Loss.

Non-current assets classified as held for sale are presented separately from the other assets in the Consolidated Balance Sheet. The liabilities classified as held for sale are presented separately from other liabilities in the Consolidated Balance Sheet.

A discontinued operation is a component of the entity that has been disposed of or is classified as held for sale and that represents a separate major line of business or geographical area of operations, is part of a single coordinated plan to dispose of such a line of business or area of operations, or is a subsidiary acquired exclusively with a view to resale. The results of discontinued operations are presented separately in the Consolidated Statement of Profit and Loss.

The post-tax profit or loss of discontinued operations and the post-tax gain or loss recognised on the measurement to fair value less costs to sell or on the disposal of the assets constituting the discontinued operation shall be disclosed separately as a single amount in the Consolidated Statement of Profit and Loss.

An analysis of the single amount into the revenue, expenses and pre-tax profit or loss of discontinued operations, the related income tax expense as required by Ind AS 12 and the gain or loss recognised on the measurement to fair value less costs to sell or on the disposal of the assets constituting the discontinued operation along with the related income tax expense thereon as required by Ind AS 12 may be presented in the notes or in the Consolidated Statement of Profit and Loss.

q. Provisions (other than for employee benefits) and contingent liabilities

Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The expenses relating to a provision is presented in the Consolidated Statement of Profit and Loss net of any reimbursement.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows specific to the liability. The unwinding of the discount is recognised as finance cost.

A provision for onerous contracts is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Group recognises any impairment loss on the assets associated with that contract.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but will probably not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision disclosure is made.

A contingent asset is not recognised but disclosed in the Group financial statements where an inflow of economic benefit is probable.

Commitments includes the amount of purchase order (net of advance) issued to parties for completion of assets. Provisions, contingent assets, contingent liabilities and commitments are reviewed at each closing date.

r. Corporate Social Responsibility ("CSR") expenditure

CSR expenditure incurred by the Group is charged to the Consolidated Statement of the Profit and Loss.

s. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM").

The Board of Directors of the Group have been identified as being the CODM by the management of the Group. Refer Note 34 for segment information presented.

q. Cash dividend

The Group recognises a liability to make cash distributions to equity holders when the distribution is authorised and the distribution is no longer at the discretion of the Group. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders (in the case of interim dividend it is approved by Board of Directors. A corresponding amount is recognised directly in equity.







r. Recent pronouncement on Indian Accounting Standards (Ind AS):

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards. There is no such notification which would have been applicable from April 01, 2022. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective:

(i) Interest Rate Benchmark Reform - Phase 2: Amendments to Ind AS 109, Ind AS 107, Ind AS 104 and Ind AS 116

The amendments provide temporary reliefs which address the financial reporting effects when an interbank offered rate (IBOR) is replaced with an alternative nearly risk-free interest rate (RFR).

The amendments include the following practical expedients:

- -A practical expedient to require contractual changes, or changes to cash flows that are directly required by the reform, to be treated as changes to a floating interest rate, equivalent to a movement in a market rate of interest
- -Permit changes required by IBOR reform to be made to hedge designations and hedge documentation without the hedging relationship being discontinued
- -Provide temporary relief to entities from having to meet the separately identifiable requirement when an RFR instrument is designated as a hedge of a risk component

These amendments have no impact on the consolidated financial statements of the Group. The Group intends to use the practical expedients in future periods as and when it become applicable,

(ii) Amendments to Ind AS consequential to Conceptual Framework under Ind AS

The Framework is not a Standard and it does not override any specific standard. Therefore, this does not form part of a set of standards pronounced by the standard-setters. While, the Framework is primarily meant for the standard-setter for formulating the standards, it has relevance to the preparers in certain situations such as to develop consistent accounting policies for areas that are not covered by a standard or where there is choice of accounting policy, and to assist all parties to understand and interpret the Standards.

The amendments made in following standards due to Conceptual Framework for Financial Reporting under Ind AS .includes amendment of the footnote to the definition of an equity instrument in Ind AS 102- Share Based Payments, footnote to be added for definition of liability i.e. definition of liability is not revised on account of revision of definition in conceptual framework in case of Ind AS 37 - Provisions, Contingent Liabilities and Contingent Assets etc.

The MCA has notified the Amendments to Ind AS consequential to Conceptual Framework under Ind AS vide notification dated June 18, 2021, applicable for annual periods beginning on or after April 1, 2021. Accordingly, the Conceptual Framework is applicable for preparers for accounting periods beginning on or after 1 April 2021.

These amendments have no impact on the consolidated financial statements of the Group

(iii) Ind AS 116: COVID-19 related rent concessions

MCA issued an amendment to Ind AS 116 Covid-19-Related Rent Concessions beyond 30 June 2021 to update the condition for lessees to apply the relief to a reduction in lease payments originally due on or before 30 June 2022 from 30 June 2021. The amendment applies to annual reporting periods beginning on or after 1 April 2021. In case a lessee has not yet approved the consolidated financial statements for issue before the issuance of this amendment, then the same may be applied for annual reporting periods beginning on or after 1 April 2020.

These amendments have no impact on the consolidated financial statements of the Group

(iv) Ind AS 103: Business combination

The MCA clarified that for the purpose of this Ind AS, acquirers are required to apply the definition of asset and liability given in the framework for preparation and presentation of consolidated financial statements with Indian Accounting standards rather than the conceptual framework. Therefore, the acquirer does not recognise those costs as part of applying the acquisition method. Instead, the acquirer recognises those costs in its post-combination consolidated financial statements in accordance with other Ind AS.

These amendments have no impact on the consolidated financial statements of the Group.

(v) Amendment to Ind AS 105, Ind AS 16 and Ind AS 28

In the definition of "Recoverable amount" the words "the higher of an asset's fair value less costs to sell and its value in use" are replaced with "higher of an asset's fair value less costs of disposal and its value in use". The consequential amendments are made in Ind AS 105, Ind AS 16 and Ind AS 28.

These amendments have no impact on the consolidated financial statements of the Group



(This space is intentionally left blank)





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued) (All amounts are in Indian Rupees in millions, unless otherwise stated)

4 Property, plant and equipment

| Gross carrying value Balance at 1 April 2020 Additions Release at 31 Mooch 2027 | timpi overnesis | | Omee equipment | Computers | Electrical equipments | Air conditioners | Iotal |
|---|-----------------|--------|----------------|-----------|-----------------------|------------------|---------|
| Balance at 1 April 2020 Additions Release of 213 Mooch 2022 | | | | | | | |
| Additions Release as at 21 March 2022 | 163.77 | 120.73 | 77.29 | 238.16 | 17.89 | 22.02 | 639.86 |
| Rajones as at 11 March 2077 | 22.12 | 8.71 | 41.89 | 17.80 | | 0.56 | 91.08 |
| Dalance as at 31 Planch 2022 | 185.89 | 129,44 | 119.18 | 255.96 | 17.89 | 22.58 | 730.94 |
| Accumulated depreciation | | | | | | | |
| Balance at 1 April 2020 | 78.76 | 31.73 | 41.40 | 158.60 | 4.67 | 6.29 | 321.45 |
| Depreciation for the year | 37.49 | 13.14 | 19.61 | 37.62 | 5.03 | 5.40 | 118.35 |
| Balance as at 31 March 2022 | 116.25 | 44.87 | 1019 | 196.22 | 9.70 | 69'11 | 439.80 |
| Net carrying value at 31 March 2021 | 69.64 | 84.57 | 58.11 | 59.74 | 8.19 | 10.89 | 291.14 |
| Balance at 1 April 2021 | 185.89 | 129,44 | 119.18 | 255.96 | 17.89 | 22.58 | 730.94 |
| Reclassification of Gross Block | 41.16 | (1427) | 2.00 | (06 017 | | 16.471 | |
| Additions | | 0.55 | 4,68 | 48.43 | | - | 55.58 |
| Disposals | (0.18) | (2.89) | (31.14) | (4.37) | | (1.94) | (40.78) |
| Balance as at 31 March 2022 | 228.87 | 112.83 | 27.72 | 289.12 | | 14.17 | 745.74 |
| Accumulated depreciation | | | | | | | |
| Balance at 1 April 2021 | 116.25 | 44.87 | 10.19 | 196.22 | 9.70 | 11.69 | 439.80 |
| Reclassification/adjustments of Accumulated depreciation | 17.82 | (3.32) | 6.19 | (7.69) | (8.60) | (4.39) | 4 |
| Depreciation for the year | 41.44 | 10.54 | 25.49 | 36.77 | | 2.31 | 116.73 |
| Disposals | (0.18) | (1,63) | (15.48) | (4.00) | | (1.79) | (23.28) |
| Balance as at 31 March 2022 | 175.33 | 50,46 | 77.27 | 221.30 | | 7.82 | 533.25 |
| Net carrying value at 31 March 2022 | 53.54 | 62.37 | 20.45 | 67.82 | 1,95 | 6.35 | 212.49 |



(This space is intentionally left blank)

1sissA



Notes to Consolidated financial statements (continued)
(All amounts are in Indian Rupees in millions, unless otherwise stated)

5 (a) Right-of-use assets

| Particulars | Buildings | Tota |
|-------------------------------------|-----------|--------|
| Gross carrying value | | |
| Balance at 1 April 2020 | 438.37 | 438.37 |
| Additions | 9.30 | 9.30 |
| Balance at 31 March 2021 | 447.67 | 447.67 |
| Accumulated depreciation | | |
| Balance at 1 April 2020 | 87.60 | 87.60 |
| Depreciation for the year | 91.60 | 91.60 |
| Balance at 31 March 2021 | 179.20 | 179.20 |
| Net carrying value at 31 March 2021 | 268.47 | 268.47 |

| Particulars | Buildings | Tota |
|-------------------------------------|-----------|---------|
| Gross carrying value | Toward Hu | 2000000 |
| Balance at 1 April 2021 | 447.67 | 447.67 |
| Additions | 24.36 | 24.36 |
| Balance as at 31 March 2022 | 472.03 | 472.03 |
| Accumulated depreciation | | |
| Balance at 1 April 2021 | 179.20 | 179.20 |
| Depreciation for the year | 91,95 | 91.95 |
| Balance as at 31 March 2022 | 271.15 | 271.15 |
| Net carrying value at 31 March 2022 | 200.88 | 200.88 |



(This space is intentionally left blank)



Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

5 (b) Lease liabilities

A The following is the movement of lease liabilities during the year ended 31 March 2021

| #AND TOOK | As at |
|--------------------------------|---------------|
| Particulars | 31 March 2021 |
| Opening Balance | 427.48 |
| Additions | 9.13 |
| Deletions | |
| Interest expense for the year | 33.04 |
| Rent concession | (26.50) |
| Repayment of lease liabilities | (90.15) |
| Closing Balance | 353.00 |

The following is the movement of lease liabilities during the year ended 31 March 2022

| Particulars | As at |
|--------------------------------|---------------|
| a at the unit of | 31 March 2022 |
| Opening Balance | 353.00 |
| Additions | 23.86 |
| Interest expense for the year | 27.51 |
| Repayment of lease liabilities | (129.57) |
| Closing Balance | 274.80 |

B The following is the break-up of lease liabilities

| Particulars | As at | As at |
|-----------------------------|---------------|---------------|
| I at GCum75 | 31 March 2022 | 31 March 2021 |
| Current lease liability | 99.58 | 96.24 |
| Non-current lease liability | 175.20 | 256.76 |
| Total | 274.78 | 353.00 |

C The table below provides details regarding the contractual maturities of lease liabilities on an undiscounted basis:

| Particulars | As at | As at |
|----------------------|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Less than one year | 120.78 | 119.62 |
| One to five years | 179.09 | 287.46 |
| More than five years | | - |
| Total | 299.87 | 407.08 |

D Amount recognized in Consolidated Statement of Profit and Loss

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-------------------------------------|-------------------------------------|
| Interest on lease liabilities- presented under finance costs | 27.51 | 33.04 |
| Depreciation on right-of-use assets- presented under depreciation and amortisation expenses | 91.95 | 90.20 |
| Expense relating to short-term leases and low value assets- presented under other expenses- rent | 22.91 | 26.62 |
| Less: Rent concession due to COVID-19- presented under other expenses- rent | (6.62) | (26.50) |

During the year ended 31 March 2022, the Group incurred expenses amounting to Rs. 14.31 million (31 March 2021: Rs. 26.62 million) for short-term leases and leases of low-value assets. For the year ended 31 March 2022, the total cash outflows for leases, including short-term leases and low-value assets amounted to Rs. 137.26 million (31 March 2021: Rs. 116.78 million).

During the year ended 31 March 2022, the Group received rent concessions as a consequence of COVID-19. Since, the change in lease payments is less than the consideration for the lease immediately preceding the change and there was no substantive change to other terms and conditions of the lease, the Group has elected to apply the practical expedient which permits a lessee to elect not to assess whether a COVID-19-related rent concession as a lease modification. Consequently, the change in lease payments resulting from the COVID-19-related rent concession is accounted for in the same way it would account for the change applying Ind AS 116 if the change were not a lease modification.

Impact of the Global Pandemic ("COVID-19")

The Group does not foresee any large-scale contraction in demand which could result in significant down-sizing of its employee base rendering the physical infrastructure redundant. The leases that the Group has entered with lessors for buildings are long term in nature and no changes in terms of those leases are expected due to the COVID-19.



(This space is intentionally left blank)



Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

6 Goodwill

| Corner annual law and law | |
|-------------------------------------|--------|
| Balance at 1 April 2020 | 409.80 |
| Acquisition | |
| Balance as at 31 March 2022 | 409.80 |
| Accumulated impairment loss | |
| Balance at 1 April 2020 | |
| For the year | |
| Balance as at 31 March 2022 | |
| Net carrying value at 31 March 2021 | 409.80 |
| Gross carrying value | |
| Balance at 1 April 2021 | 409.80 |
| Acquisition | • |
| Balance as at 31 March 2022 | 409.80 |
| Accumulated impairment loss | |
| Balance at 1 April 2021 | 331 |
| For the year | * |
| Balance as at 31 March 2022 | |
| Net carrying value at 31 March 2022 | 409.80 |

Impairment testing for goodwill:

For the purpose of impairment testing, goodwill is allocated to Health benefit administration which is considered as eash generating unit (CGU).

The recoverable amount of the CGU is based on value in use, estimated using discounted cash flows.

The key assumptions used in the estimation of the recoverable amount are set out below. The value assigned to the key assumptions represents management's assessment of future trends in the relevant industries and have been based on historical data from both external and internal source.

| Particulars | 31 March 2022 | 31 March 2021 |
|--|---------------|---------------|
| Discount rate | 16.30% | 16.30% |
| Terminal growth rate | 4.00% | 4,00% |
| Budgeted EBITDA ⁽⁴⁾ growth rate | 18.00% | 18.00% |

⁽a) EBITDA refers to Earnings before interest, tax, depreciation and amortisation.

The discount rate is a post-tax measure estimated based on the historical industry average weighted-average cost of capital.

The cash flow projections includes specific estimates for five years and a terminal growth rate thereafter. The terminal growth rate has been determined based on management's estimates of long-term compound annual EBITDA growth rate.

Budgeted EBITDA has been estimated taking into account past experience derived as follows:

(i) Revenue growth has been projected taking into account the average growth rate levels experienced over past five years and the estimated sales volume and price growth for the next five year. It has been assumed that the sales price would increase in line with forecast inflation over the next five year, Note: Based on the assessment, the Group determined that the estimated recoverable value of the CGU is higher than its carrying cost and consequently, the Group has not recorded any impairment loss following the guidance under Ind AS 36 "Impairment of assets". The Group has performed sensitivity analysis for all key assumptions, including the eash flow projections consequent to the change in estimated future economic conditions arising from the effects due to COVID-19 and is unlikely to cause the carrying amount of the CGU exceed its estimated recoverable amount.





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rapees in millions, unless otherwise stated)

7 Other intangible assets

| Particulars | Software and licenses | Customer relationship Customer contracts | Customer contracts | Total | Intangible under |
|--|-----------------------|--|--------------------|---------|--|
| Gross carrying value | | | | | - Contraction of the Contraction |
| Balance at 1 April 2020 | 374.00 | 297.76 | 00.00 | 30 C03 | 13.87 |
| Additions | 4 | | 2000 | 00.400 | 70,61 |
| Additions of the second of the | 46.20 | * | | 46.20 | 12.86 |
| Capitalisation of Intangrole assets under development | | • | ě | | (19.74) |
| Non-current assets classified as held for sale (Refer Note 44) | (16.19) | | ٠ | (16,19) | |
| Balance as at 31 March 2022 | 404.01 | 297.76 | 20.30 | 722.07 | 6.94 |
| Accumulated amortisation | | | | | |
| Balance at 1 April 2020 | 285.73 | 105.53 | 4.45 | 305.71 | , |
| For the year | 74.34 | 29.76 | 2.54 | 106.64 | 20 |
| Non-current assets classified as held for sale (Refer Note 44) | (3.75) | | | (3.75) | |
| Balance as at 31 March 2022 | 356.32 | 135.29 | 66.9 | 498 60 | |
| Net carrying value at 31 March 2021 | 47.69 | 162.47 | 13.31 | 223.47 | 6.94 |
| Gross carrying value | | | | | |
| Balance at 1 April 2021 | 404.01 | 297.76 | 20.30 | 722.07 | 6.94 |
| Additions | 15.74 | | • | 15.74 | 19 15 |
| Disposals | (0.11) | | | (0.11) | |
| Balance as at 31 March 2022 | 419.64 | 297.76 | 20.30 | 737.70 | 64.61 |
| Accumulated amortisation | | | | | |
| Balance at 1 April 2021 | 356.32 | 135.29 | 6.99 | 498.60 | 9 |
| For the year | 43.31 | 29.55 | 2.54 | 75.40 | • |
| Disposals | (0.11) | | | (0,11) | |
| Balance as at 31 March 2022 | 399.52 | 164.84 | 9,53 | 573.89 | , |
| Net carrying value at 31 March 2022 | 20.12 | 133 03 | 10.31 | **** | **** |

^{*} Intangible assets under development are based on internal technical feasibility study carried out by management with the intention to complete the self generated intangible assets. Management has assessed that such intangible assets will generate future economic benefits for the Group and therefore meet the capitalization criteria in accordance with Ind AS 38 - Intangible assets.





(All amounts are in Indian Rupees in millions, unless otherwise stated) Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

7 Other intangible assets (continued)

* Intangible assets under development ageing schedule

| Particulars | | Amount in Intangible assets under developm | issets under develops | nent for a period of | |
|--------------------------------|------------------|--|-----------------------|----------------------|-------|
| | Less than 1 year | 1-2 years | 2-3 years | More than 3 years | Total |
| Project in progress | 27.67 | 6.94 | | | 64.61 |
| Projects temporarily suspended | | • | | | |
| Fotal | 27.67 | 6.94 | | | 1979 |

| | Amount in Intangible assets under development for a peric | |
|-------------|---|--|
| I THE PARTY | culars | |

| Particulars | | Amount in Intangible a | assets under develop | oment for a period of | |
|--------------------------------|------------------|------------------------|----------------------|-----------------------|-------|
| | Less than I year | 1-2 years | 2-3 years | More than 3 years | Total |
| Project in progress | | 6.94 | | | 6.94 |
| Projects temporarily suspended | • | | * | 33* | • |
| Total | * | 10.9 | | , | F6 9 |









Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

8 Non-current financial assets

8 (a) Investments

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|--|------------------------|------------------------|
| (i). Quoted equity shares | | |
| Equity shares at Fair Value through Other Comprehensive Income (FVOCI): 124,992 (31 March 2021: 124,992) equity shares of Rs. 5 each, fully paid up of The New India Assurance Company Limited | 13.96 | 19.29 |
| (ii). Unquoted equity shares Investment in equity shares at Fair Value through Other Comprehensive Income (FVOCI): | | |
| 13,719 (31 March 2021: 13,719) equity shares of Rs. 1 each, fully paid up of Healthvista India Private Limited | 54.93 | 54.93 |
| 5,000 (31 March 2021: 5,000) equity shares of Rs. 100 each, fully paid up of Swasth Digital Health Foundation | 0.50 | 0.50 |
| | 69.39 | 74.72 |
| Aggregate amount of quoted investments and market value thereof Aggregate amount of unquoted investments | 13.96 55.43 | 19.29 55.43 |

8 (b) Other financial assets

| Particulars | As at | As at |
|---|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Considered good - Unsecured | | |
| Security deposits | 14.98 | 32.70 |
| Earnest money deposit ("EMD") | 6.85 | 9.67 |
| Deposits with original maturity of more than 12 months* | 12.09 | 0.62 |
| Interest accrued but not due on fixed deposits | 0.13 | |
| Credit impaired | | |
| Security deposits | 924 1 | 0.55 |
| Less: Provision for doubtful security deposits | 7 | (0.55) |
| | 34.05 | 42.99 |

^{*} The above includes bank deposits amounting to Rs Nil (31 March 2021: Rs 0.62 million) placed with bank against which bank guarantee have been issued to insurance companies.

The Group's exposure to credit risk is disclosed in Note 32C (ii).

9 Non-Current tax assets (net)

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|--|------------------------|------------------------|
| Advance tax and tax deducted at source, net of provisions [(Provision Rs 1093.91 million (31 March 2021 Rs 897.18 million)] | 492.47 | 303.12 |
| | 492.47 | 303.12 |

10 Deferred tax assets (net)

| Particulars | As at 31 March 2022 | As at |
|--|------------------------|---------------|
| Deferred tax assets | 31 March 2022 | 31 March 2021 |
| Provision for employee benefits | 39.92 | 29.91 |
| Allowance for expected credit losses on trade receivables and | 62.44 | 90.63 |
| unbilled receivables and provisions for doubtful advances and | 02.44 | 90.03 |
| deposits | | |
| Security deposits at amortised cost | 0.78 | 1.35 |
| Temporary differences on accrued expenses | 11.23 | 6.23 |
| Lease liabilities | 69.16 | 88.13 |
| Other items | | 5.30 |
| Total deferred tax assets | 183.53 | 221.55 |
| Deferred tax liabilities | | |
| Excess of depreciation on fixed assets under Income tax act, 1961 over depreciation under Companies Act | (29.14) | (47.56) |
| Right of use assets | (50.55) | (67.57) |
| Other items Total deferred tax liabilities | (8.64) | |
| althcar | (88.33) | (115.13) |
| Deferred tax assets (nct)* | 95.20 | 106.42 |
| (* \ \(\tau \) \(\ta | | |

^{*} Refer Note 35.



Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

* Refer Note 35.

11 Other non-current assets

| Particulars | As at | As at |
|------------------|---------------|---------------|
| an iteliara | 31 March 2022 | 31 March 2021 |
| Prepaid rent | 5.78 | 0.35 |
| Capital advances | 0.78 | 8.41 |
| | 6.56 | 8.76 |







Medi Assist Flemincare Services Limited

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

12 Current - Financial assets

12 (a) Investments

| | Particulars | As at | As a |
|------|---|---------------|---------------|
| 52 | | 31 March 2022 | 31 March 2021 |
| (i) | Investments in mutual funds - Unquoted-Fair Value through Profit and Loss (FVTPL) | 1,895.04 | 1,030.89 |
| (ii) | Advance given for business acquisition | 50.00 | |
| | | 1,945.04 | 1,030.89 |
| | Aggregate amount of unquoted investments | 1,945.04 | 1,030.89 |

12 (b) Trade receivables

| Particulars | As at | As n |
|--|---------------|--------------|
| | 31 March 2022 | 31 March 202 |
| Considered good - Unsecured | 470.14 | 433.61 |
| Credit impaired - Unsecured | 207.49 | 283.00 |
| Total receivables | 677.63 | 716.61 |
| Less: Allowance for expected credit losses | (207.49) | (283.00) |
| Total (A) | 470.14 | 433.61 |
| Unbilled receivables | | |
| Considered good - Unsecured | | |
| Unbilled receivables | 717.56 | 777.19 |
| Unsecured, considered doubtful | | |
| Unbilled receivables | 8.38 | 42.75 |
| Less: Allowance for expected credit losses | (8.38) | (42.75) |
| Total (B) | 717.56 | 777.19 |
| Total (A+B) | 1,187.70 | 1,210.80 |

The Group's exposure to credit risk and loss allowances are disclosed in Note 32C (ii).

Trade receivable ageing:- Outstanding for following period from due date of reciepts

As at 31 March 2022

| Particulars | Unbilled | Not due | Less than 6 Months | 6 Months - 1 Year | 1-2 Years | 2-3 Years | More than 3 Years | Total |
|---|----------|---------|--------------------|-------------------|-----------|-----------|-------------------|----------|
| Undisputed trade receivable - considered good | 717.56 | 315.02 | 37.02 | 84.27 | 17.21 | 10.89 | 5.73 | 1,187.70 |
| Undisputed trade receivable - which have significant increase in credit risk | 8.38 | \$6 | 12.29 | 8.21 | 18.75 | 33.29 | 134.95 | 215.87 |
| Undisputed trade receivable - credit impaired | 2 | 20 | | | | | | |
| Disputed trade receivable - considered good | - | | | | | | | |
| Disputed trade receivable - which have significant increase in credit risk | - | 2 | | | 7.5 | 12 | | |
| Disputed trade receivable - credit impaired | - 1 | | | | | | | |
| Total | 725.94 | 315.02 | 49.31 | 92.48 | 35.96 | 44.18 | 140.68 | 1,403.56 |
| Loss allowance | | | | | | | 2.14100 | (215.87) |
| Total | | | | | | | | 1,187.70 |

As at 31 March 2021

| Particulars | Unbilled | Not due | Less than 6 Months | 6 Months - 1 Year | 1-2 Years | 2-3 Years | More than 3 Years | Total |
|---|----------|---------|--------------------|-------------------|-----------|-----------|-------------------|----------|
| Undisputed trade receivable - considered good | 777.19 | 379.59 | (33.17) | 23.56 | 31.58 | 26,27 | 5.78 | 1,210.80 |
| Undisputed trade receivable - which have significant increase in credit risk | 42,75 | | 3.92 | 35.57 | 46.74 | 91.79 | 104.98 | 325.75 |
| Undisputed trade receivable - credit impaired | | | 93 | 92 | 100 | 12 | ¥ | 112 |
| Disputed trade receivable - considered good | - | | | - | 115.6 | | | |
| Disputed trade receivable - which have significant increase in credit risk | * | | | Ÿ. | | | Ş | 1 |
| Disputed trade receivable - credit impaired | | | | | 240 | | | 12 |
| Total | 819.94 | 379.59 | (29.25) | 59.13 | 78.32 | 118.06 | 110.76 | 1,536.55 |
| Loss allowance | | | | 10127 | | | | (325.75) |
| Total | | | | | | | | 1,210.80 |

12 (c) Cash and cash equivalents

| Particulars | As at | As at |
|---|-----------------|---------------|
| 32235333369 | 31 March 2022 | 31 March 2021 |
| Cash on hand | 0.26 | 0.25 |
| Balances with banks | (2 <u>100</u>) | 3,700,00 |
| In current accounts | 145.69 | 633.06 |
| Deposit with original maturity of less than three months* | * | 0.58 |
| | 145.95 | 633.89 |
| The Company's exposure to credit risk is disclosed in Note 32C. | | |

* Includes bank deposit of Rs. Nil (31 March 2021: Rs 0.54 million) placed with bank against which bank guarantee have been issued to insurance companies.





PRODUCTION AND ADDRESS OF THE PARTIES

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

12 (d) Bank balances other than cash and cash equivalents

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|--|------------------------|------------------------|
| B. A. | 31 March 2022 | 31 March 2021 |
| Deposits with original maturity of more than three months but less than twelve months * | 478.15 | 512.22 |
| Balances with banks | 0.5577.57 | - |
| -Balance with Self funded schemes ** | 1.23 | 1.22 |
| | 1.23 | 1.23 |
| * The above includes bank denosits amounting to Rs 1 50 million (31 March 2021; Rs 1 26 million) aloned with bankers and | 479.38 | 513.45 |

^{*} The above includes bank deposits amounting to Rs 1.50 million (31 March 2021; Rs. 3.76 million) placed with bankers against which bank guarantees have been issued to customers and lien against corporate credit cards.

The Group's exposure to credit risk is disclosed in Note 32C (ii).

12 (e) Other financial assets

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|---|------------------------|------------------------|
| Considered good - Unsecured | | 377733734 |
| Security deposits | 55.24 | 39.36 |
| Earnest money deposit | 6.73 | 39.30 |
| Accrued interest | 3.50 | 5.30 |
| Other receivables* | 183.64 | 147.90 |
| Unsecured, considered doubtful | | |
| Inter-corporate deposit ** | | 40.00 |
| Less: Allowance for doubtful deposits | | (40.00) |
| Interest accrued but not due on ICD | | 4.48 |
| Less: Allowance for interest accrued on ICD | | (4.48) |
| Credit impaired | | |
| Security deposits | 0.08 | 0.08 |
| Less: Allowance for doubtful deposits | (0.08) | (0.08) |
| Other receivables | 16.15 | 15.35 |
| Less: Allowance for doubtful receivables | (16.15) | (15.35) |
| | 249.11 | 192.56 |

^{*} Refer Note 40.

13 Other current assets

| As at 31 March 2022 | As a: 31 March 2021 |
|------------------------|---|
| 77.770.00 | or materials |
| 154 50 | 79.66 |
| | 28.22 |
| | 4.02 |
| 17.90 | 11.26 |
| | |
| 16.14 | 18.43 |
| | (18.43) |
| 265.86 | 123.16 |
| | 31 March 2022 154.59 87.51 5.86 17.90 16.14 (16.14) |



(This space is intentionally left blank)

La



^{*} Includes bank deposit of Rs. 22.18 million (31 March 2021; Rs. 229.14 million) which are under lien with bank towards bank guarantee availed by the Holding company.

^{**} Balance with Self funded schemes represent funds received from corporates for the purpose of providing health benefit services to their employees.

^{*} Refer Note 47.

^{**} Represents inter-corporate deposit ("ICD") provided to Mobiefit Technologies Private Limited ("MTPL"). The term of ICD is 60 months from the date of disbursement and carries an interest of 8%, payable on maturity at 30 August 2021.

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

14 Equity share capital

| Particulars | As at | As at |
|---|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Authorised:* | | |
| 90,700,000 (31 March 2021: 45,200,000) equity shares of Rs 5 each (31 March 2021: Rs 10 each) | 453.50 | 453.50 |
| | 453.50 | 453.50 |
| Issued, subscribed and paid-up capital | | |
| 68,859,212 (31 March 2021: 37,181) equity shares of Rs 5 each (31 March 2021: Rs 10 each) *** | 344.30 | 0.37 |
| | 344.30 | 0.37 |

^{*} Pursuant to a resolution passed by the Shareholders of the Company on 15 March 2021 through extra-ordinary general meeting, the authorized share capital of the Company of Rs. 453.50 million divided into 45,200,000 Equity Shares of Rs. 10 each, 140,000 Preference Shares of Rs. 10 each and 5 Series A Compulsorily Convertible Preference Shares of Rs 20,000 each, were reclassified to Rs. 453.5 million divided into 45,350,000 Equity Shares of Rs. 10 each.

a) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting year:

| Particulars | As at 31 March 2022 | | As at 31 March 2021 | |
|--|---------------------|--------|---------------------|--------|
| | Number of shares | Amount | Number of shares | Amount |
| Equity shares | | | | |
| Balance at the beginning of the year | 37,181 | 0.37 | 36,082 | 0.36 |
| Shares issued during the year* | | ** | 1,099 | 0.01 |
| Sub-division of shares during the year from Rs.10 to Rs.5 each** | 37,181 | | | 0.01 |
| Bonus shares issued during the year** | 68,784,850 | 343.93 | | |
| Balance at the end of the year | 68,859,212 | 344.30 | 37,181 | 0.37 |

[•] Pursuant to a resolution passed by Board of Directors of the Company on 4 March 2021, Company has converted 9,175 Redeemable Preference Shares into 9,175 Series B Compulsorily Convertible Preference Shares ("Series B CCPS") and then extinguished the above 9,175 Series B CCPS of Rs 10 each by issue of 1,099 Equity Shares of Rs. 10 each effective 5 March 2021.

b) Rights, preference and restrictions attached to the equity shares:

The Company has single class of equity shares having a par value of Rs. 5 each. Each holder of equity shares is entitled to one vote per share. Voting rights cannot be exercised in respect of shares on which any call or other sum presently payable has not been paid. Failure to pay any amount called up on shares may lead to forfeiture of shares.

The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) List of shareholders holding more than 5% shares of a class of shares

| Particulars | As at 31 March 2022 | | As at 31 March 2021 | |
|---|---------------------|---|---------------------|---|
| | Number of shares | % of Holding | Number of shares | % of Holding |
| Equity shares of Rs. 5 each fully paid-up (31 March 2021: Rs 10 each) held by | 7 | | | |
| Medimatter Health Management Private Limited | 18,703,348 | 27.16% | 10,099 | 27.16% |
| Bessemer Health Capital LLC | 6,606,084 | 9.59% | 3,567 | 9.59% |
| Investcorp India Asset Managers Pvt. Ltd. | | 100000000000000000000000000000000000000 | 0,000 | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| Investment manager of IDBI Trusteeship Services Limited, A/C Investcorp Infrastructure Fund 1, A/C Investcorp Private Equity Fund I (earlier known as IDFC Trustee Company Limited, A/C IDFC Infrastructure Fund 3, A/C IDFC Private Equity Fund III) | 14,910,452 | 21.65% | 8,051 | 21.65% |
| Bessemer India Capital Holdings II Limited | 24,731,608 | 35.92% | 13,354 | 35.92% |







^{*} Pursuant to a resolution passed by the Shareholders of the Company on 7 April 2021 through extra-ordinary general meeting, the authorized share capital of the Company of Rs. 453.5 million divided into 45,350,000 Equity Shares of Rs. 10 each were sub-divided to Rs. 453.5 million divided into 90,700,000 Equity Shares of Rs. 5 each.

^{**} Pursuant to a resolution passed by the Shareholders on 7 April 2021 and subsequent allotment on 9 April 2021, the Company has sub-divided the face value of its equity shares from Rs 10 each to Rs 5 each. Further, the Company has allotted 68,784,850 equity shares of face value of Rs. 5 each by way of bonus issue to its shareholders and consequently the paid-up share capital of the Company has been increased to 68,859,212 equity shares of face value of Rs 5 each and the Board authorised for appropriate adjustments on allotment of share split and bonus shares to the outstanding options granted to the employees under the ESOP scheme.

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

d) Shares reserved for issue under employee stock option scheme of the company

| Particulars | As at 31 March 2022 | | As at 31 March 2021 | |
|---|---------------------|--------|---------------------|--------|
| | Number of options | Amount | Number of options | Amount |
| Jnder Employee Stock Option Scheme, 2013: 23,40,928 (31 March 2021: | 2,340,928 | 11.70 | 654 | 0.01 |

Refer Note 31 for ESOP scheme details.

- e) The Company has not bought back any class of equity shares during the period of five year immediately preceding the balance sheet date.
- f) The Company's objective for capital management is to maximise shareholder value, safeguard business continuity and support the growth of the Company. The Company determines the capital requirement based on annual operating plans, long-term and other strategic investment plans. The funding requirements are met through equity, external borrowings and operating cash flows generated.

g) Promoter's Shareholdings

As at March 31, 2022

| Shares held by promoters at the | % Change during | | | |
|--|-----------------|--------------------------------|----------|--|
| Promoter name | No of shares | % of total number of shares | the year | |
| Dr Vikram Jit Singh Chhatwal | 2,539,092 | 3.69% | | |
| Medimatter Health Management Private Limited | 18,703,348 | 27.16% | | |
| Medimatter Health Management Private Limited jointly with Dr. Vikram Jit Singh Chhatwal | 537,080 | 0.78% | • | |
| Bessemer India Capital Holdings II Limited | 24,731,608 | 35.92% | * | |
| Total | 46,511,128 | 67.55% | | |

As at March 31, 2021

| Shares held by promoters at the | % Change during | | | |
|--|-----------------|--------------------------------|----------|--|
| Promoter name | No of shares | % of total number of shares | the year | |
| Dr Vikram Jit Singh Chhatwal | 1,371 | 3.69% | | |
| Medimatter Health Management Private Limited | 10,099 | 27.16% | | |
| Medimatter Health Management Private Limited jointly with Dr. Vikram Jit Singh Chhatwal | 290 | 0.78% | - | |
| Bessemer India Capital Holdings II Limited | 13,354 | 35.92% | | |
| Total | 25,114 | 67.55% | | |







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

15 Other equity

| Particulars | Notes | As at 31 March 2022 | As a 31 March 202 |
|--|--------|------------------------|----------------------|
| Securities premium * | (2) | | |
| Debenture redemption reserve | (i) | 745.87 | 1,089.79 |
| Retained earnings | (ii) | | |
| Employee stock option reserve | | 2,372.83 | 1,756.98 |
| | (iii) | 100.37 | 77.33 |
| Other equity | (iv) | 369.85 | 369.85 |
| Share application pending allotment | | | |
| Amalgamation adjustment reserve | (v) | (172.15) | |
| Demerger deficit balance | (v) | (370.18) | (370.18) |
| General reserve | | 1.36 3,047.95 | 1.36 2,925.13 |
| Securities premium | | | |
| Balance at the beginning of the year | | 1 000 70 | F55 00 |
| Movement during the year | | 1,089.79 | 566.80 |
| Premium on issue of equity shares | | | 522.99 |
| Utilisation of securities premium on issue of bonus shares | | (343.92) | 322.99 |
| Balance at the end of the year | (i) · | 745.87 | 1.080.70 |
| | | /45.0/ | 1,089.79 |
| Debenture redemption reserve | | | |
| Balance at the beginning of the year | | | 1.36 |
| Movement during the year | | | |
| Transfer of Debenture redemption reserve | | | (1.36) |
| Balance at the end of the year | (ii) | | - |
| Retained earnings comprises of the Company's prior years' undistributed earnings after taxes | | | |
| Balance at the beginning of the year | | 1.756.00 | 1 400 00 |
| Movement during the year | | 1,756.99 | 1,490.09 |
| Total comprehensive income for the year | | 616.46 | 266.00 |
| Dividend paid* | | 616.46 | 266.90 |
| Balance at the end of the year | | (172.15) 2,201.30 | 1,756.99 |
| Employee stock option reserve | | | |
| Balance at the beginning of the year | | | 2000 |
| Movement during the year | | 55.75 | 55.75 |
| Employee stock option compensation cost (net) | | | |
| Balance at the end of the year | com - | 23.04 | |
| | (iii) | 78.79 | 55.75 |
| Other equity | | | |
| Balance at the beginning of the year | | 369.85 | 369.85 |
| Movement during the year | 2000 E | | _ |
| Balance at the end of the year | (iv) | 369.85 | 369.85 |
| Demerger deficit balance | | | |
| Balance at the beginning of the year | | (370.18) | (370.18) |
| Movement during the year | | | |
| Balance at the end of the year | (v) | (370.18) | (370.18) |
| General reserve | | | |
| Balance at the beginning of the year | | 1.36 | 2 |
| Movement during the year | | 1.50 | |
| Transfer of Debenture redemption reserve | | | 1.36 |
| Balance at the end of the year | | 1.36 | 1.36 |
| | - | 3,026.99 | 2,903.56 |
| Purpose | _ | 210,000,0 | al delical |

S.No Purpose

(i) Securities premium

Securities premium is used to record premium received on issue of shares. The reserve is utilized in accordance with the provision of Companies Act, 2013.

(ii) Debenture redemption reserve

The company has issued debentures in India and as per the provisions of Companies Act, 2013, is required to create debenture redemption reserve out of the profits of the company available for payment of dividend.

(iii) Employee stock option reserve

Share based payment reserve is used to recognise the fair value of equity settled share based payments provided to the employees. For further details refer Note 31(a) and 31(b) for ESOP scheme details.

Preference suppose and debentures were initially recognized as financial liability in accordance with the nature of the instrument of the instrument of the interest on this component is recognized in the Consolidated Statement of Profit and Loss and classified as interest expense.



Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

(v) Demerger deficit balance

The reserve arising on account of demerger of CH business.

Dividends*

Final dividend on Equity Shares at the rate of 37.80% [i.e. Rs.1.89/- (Rupees One rupee and paise eighty nine only)] per Equity Share of face value of Rs. 5/- (Rupees Five Only) was declared for the financial year ended March 31, 2022.







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

Non-current financial liabilities

16 Provisions (non-current)

| Particulars | As at 31 March 2022 | As a 31 March 202 |
|----------------------------------|------------------------|----------------------|
| Provision for employee benefits: | | **** |
| Gratuity (funded)* | 112.21 | 85.56 |
| *Refer Note 30 (b). | 112.21 | 85.56 |

17 Current financial liabilities

17 (a) Trade payables

| Particulars | As at | As at |
|--|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Total outstanding dues of micro, small and medium enterprises* | 32.32 | 31.11 |
| Total outstanding dues of creditors other than micro, small and medium enterprises** | 257.88 | 303.77 |
| | 290,20 | 334.88 |

^{*} Refer Note 42,

Trade payable ageing:

As at 31 March 2022

| Particulars | Unbilled | Not due | Outstanding for following period from due date of payment | | | | 7 |
|------------------------|------------|----------|---|-----------|-----------|-------------------|--------|
| | 2 22000000 | 20020000 | Less than I year | 1-2 years | 2-3 years | More than 3 years | Total |
| MSME | 8.95 | 3.86 | 0.92 | 1.37 | (A.) | | 15.10 |
| Others | 150.01 | 60.42 | 42.68 | 1.85 | 0.27 | 2.65 | 257.88 |
| Disputed dues - MSME | | 5.94 | 9.41 | 1.19 | 0.68 | | 17.22 |
| Disputed dues - Others | | | | | | | |
| Total | 158.96 | 70.22 | 53.01 | 4.41 | 0.95 | 2.65 | 290.20 |

As at 31 March 2021

| Particulars | Unbilled | Not due | Outstanding for following period from due date of payment | | | | The same of the sa |
|------------------------|------------|---------|---|-----------|-----------|-------------------|--|
| |) 12623902 | 0000000 | Less than 1 year | 1-2 years | 2-3 years | More than 3 years | Total |
| MSME | 1.11 | 3.99 | 4.80 | 0.92 | 14 | 1.69 | 12.51 |
| Others | 193.66 | (39.38) | 109.75 | + | | 39.24 | 303.27 |
| Disputed dues - MSME | | 4.11 | 9.59 | 3.58 | - | 1,31 | 18.59 |
| Disputed dues - Others | | | 0.50 | | | | 0.50 |
| Total | 194.77 | (31.28) | 124.64 | 4.50 | - | 42.24 | 334.87 |

17 (b) Other financial liabilities

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|--------------------------------|------------------------|------------------------|
| Employee benefits payable * | 61.84 | 38.68 |
| Creditors for capital goods ^ | 61.84 | 3.63 |
| Interest accrued on income tax | | 9.66 |
| Advance received* | | 61,60 |
| Other payables* | 29.71 | 60.15 |
| | 91.55 | 173.72 |
| P 0 4 51 40 | | |

^{*} Refer Note 40.

18 Other current liabilities

| Particulars | Asat | As at |
|-----------------------|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Statutory due payable | 216.13 | 224.80 |
| Other payables | 41.39 | |
| | 257.52 | 224.80 |

19 Provisions (current)

| Particulars | Note | As at 31 March 2022 | As at 31 March 2021 |
|---------------------------------------|--------|------------------------|------------------------|
| Provision for employee benefits: | 400000 | | |
| Gratuity funded | 30 (b) | 40.62 | 28.18 |
| Employee compensated absences | 30 (c) | 5.82 | 5.14 |
| 50246009696209590909090 | (A) | 46.44 | 33.32 |
| Provision for claims disallowed: | | 100,000 | |
| Balance at the beginning of the year | | 18.78 | |
| Provision created during the year | | 8.00 | 18.78 |
| Reversed/ Utilisation during the year | | (7.00) | - |
| Balance at the end of the year | (B) | 19.78 | 18.78 |
| | (A+B) | 66.22 | 52.10 |

| 20 | Current | tax | liabilities | (net) |
|----|---------|-----|-------------|-------|

ealthcare As at 31 March 2022 As at 31 March 2021 Particulars Current tax payable 81.50 81.50

^{**} Refer Note 40.

[^] Includes dues of micro, small and medium enterprises amounting to Rs.Nil (31 March 2021: 0.29).

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

21 Revenue from operations

| Particulars | | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-----|-------------------------------------|-------------------------------------|
| Revenue | | | |
| Sale of services: | | | |
| Third Party Administration (TPA) fees | | 4,174.65 | 3,236.62 |
| Add: opening contract liabilities | 22 | 1,216.08 | 1,100.33 |
| | _ | 5,390.73 | 4,336.95 |
| Less: closing contract liabilities | | (1,536.96) | (1,216.08) |
| Income from TPA services | (a) | 3,853.77 | 3,120.87 |
| Income from health management services | (b) | 43.99 | 45.88 |
| Income from license fee | | 0.44 | 7.91 |
| Less: closing contract liability | 22 | * | (5.88) |
| Oth | (c) | 0.44 | 2.03 |
| Other operating revenues: | | | |
| Business support services* | (d) | 39.90 | 58.63 |
| Total (a+b+c+d) | - | 3,938.10 | 3,227.41 |

^{*} Refer Note 40.

(A) Disaggregate of revenue information

The table below presents disaggregated revenues from contracts with customers for the below years ended by offerings and contract type. The Group believe that this disaggregation best depicts how the nature, amount, timing and uncertainty of our revenues and cashflows are effected by industry, market and other economic factors.

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-------------------------------------|-------------------------------------|
| Sale of services | | |
| Income from TPA services | 3,853.77 | 3,120.87 |
| Income from health management services | 43.99 | 45.88 |
| Income from license fee | 0.44 | 2.03 |
| Business support services | 39.90 | 58.63 |
| | 3,938,10 | 3,227.41 |
| Contract counterparties | | |
| Government customers | 471.15 | 499.25 |
| Others | 3,466.95 | 2,728.16 |
| | 3,938.10 | 3,227,41 |
| Revenue by contract type | 77 | |
| At a point in time (India) | 3,938.10 | 3,227.41 |
| | 3,938.10 | 3,227.41 |







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

(B) Contract balances

(i) The following table provides information about receivables, contract assets and contract liabilities from contract with customers.

| Particulars | Note | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|----------------------|--------|-------------------------------------|-------------------------------------|
| Trade receivables | 12 (b) | 1,187.70 | 1,210.80 |
| Contract liabilities | | 1,536.96 | 1,221.96 |

Trade receivables are non-interest bearing and are generally on payment terms of 30 to 90 days.

The contract liabilities primarily relate to billings in excess of revenues. The billing schedules agreed with customers could include periodic performance-based payments. Invoices are payable within contractually agreed credit period.

(ii) Significant changes in the contract liabilities balances during the year are as follows:

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|---|------------------------|------------------------|
| Movement in contract liabilities: | | 27.110.111.4127 |
| Opening balance | 1,221.96 | 1,100.33 |
| Revenue recognised that was included in the contract liability balance at the beginning of the year | (1,221.96) | (1,100.33) |
| Increases due to cash received, excluding amounts recognised as revenue during the year | 1,536.96 | 1,221.96 |
| Closing balance | 1,536.96 | 1,221.96 |

(C) Transaction price allocated to remaining performance obligations

The following table includes revenue expected to be recognised in the future related to performance obligations that are unsatisfied (or partially satisfied) at the reporting date.

| Particulars | As at 31 March 2022 | As at 31 March 2021 |
|-------------------|------------------------|------------------------|
| Within 1 year | 1,535.32 | 1,216.06 |
| 1-3 years | 1.64 | 4.52 |
| More than 3 years | | 1.38 |
| | 1,536.96 | 1,221.96 |







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

22 Other income

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Interest income: | | |
| on term deposits and loans | 28.51 | 41.31 |
| on other financial assets | 2.78 | 3.54 |
| on other services* | 700 | 33.45 |
| on income tax refund | | 52.04 |
| Net gain on financial assets measured at fair value through profit and loss | 46.34 | 8.94 |
| Profit on sale of investment in mutual funds | 12.35 | 11.72 |
| Profit on sale of platform business | 69.70 | 11.72 |
| Creditors/ Provision no longer required written back | 11.52 | 20.61 |
| Profit on sale of investment | | 46.42 |
| Gain on transfer of property, plant and equipment | 0.34 | 10.12 |
| Miscellaneous income | 10.93 | 7.45 |
| | 182.47 | 225,48 |
| Refer Note 40. | | - Water Lands |

23 Employee benefits expense

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-------------------------------------|-------------------------------------|
| Salaries, bonus and allowances | 1,354.71 | 1,269,74 |
| Contribution to provident and other funds* | 102.96 | 106.21 |
| Gratuity | 27.93 | 25.73 |
| Employee stock option expense ** | 23.04 | 40110 |
| Staff welfare expenses | 48.15 | 30.96 |
| | 1,556.79 | 1,432.64 |
| * Refer Note 30. | | |

^{**} Refer Note 31 (a) and (b).

24 Finance costs

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Bank guarantee commission | 0.79 | 0.52 |
| Interest on income tax | | 9.66 |
| Interest on debentures* | | 0.23 |
| Interest on bank overdraft | | 13.51 |
| Other interest | 1,20 | 0.30 |
| Interest expense on lease liabilities** | 27.51 | 33.04 |
| | 29.50 | 57.26 |
| * Refer Note 40 | | |

25 Depreciation and amortisation expenses

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|--|-------------------------------------|
| Depreciation on property, plant and equipment | 116.73 | 118.35 |
| Depreciation on right-of-use assets* | 91.95 | 90.20 |
| Amortisation on intangible assets | 75.40 | 106.64 |
| | 284.08 | 315.19 |
| * Refer Note 5(a) | Parameter and the second secon | |





^{*} Refer Note 5 (b).

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

26 Other expenses

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-------------------------------------|-------------------------------------|
| Sub-contracting expenses | 553.77 | 329.28 |
| Legal and professional | 126.69 | 119.88 |
| Allowance for expected credit losses on trade receivables and unbilled receivables | 22.14 | 153.89 |
| Repair and maintenance | 139.18 | 81.35 |
| Postage and communication | 83.55 | 73.81 |
| Printing and stationery | 141.58 | 45.53 |
| Claims disallowed | 55.68 | 44.79 |
| Power and fuel charges | 26.64 | 24.31 |
| Advertisement and business promotion | 72.62 | 21.25 |
| Travelling and conveyance | 41.66 | 16.79 |
| Security expenses | 14.51 | 15.85 |
| Corporate social responsibility | 10.70 | 13.08 |
| Enrolment card charges | 35.66 | 10.01 |
| Rates and taxes | 13.93 | 10.27 |
| Software subscription charges | 37.26 | 7.50 |
| Provision for doubtful advances | 0.55 | 3.34 |
| Provision for doubtful deposits | - | 0.55 |
| Insurance awareness initiatives | 22.11 | 2.74 |
| Loss on sale of fixed asset (Net) | 9.70 | 2.74 |
| Housekeeping charges | 4.27 | 4.66 |
| Insurance | 7.75 | 6.17 |
| Auditor's remuneration * | 12.32 | 4.50 |
| Bad debts written off | 98.57 | 61.77 |
| Less: Utilisation of provision | (98.57) | (22.96) |
| Advance written off | 7.14 | (22.90) |
| Seminar, training and conference expenses | 2.45 | 0.53 |
| Recruitment | 0.24 | 4.05 |
| Rent** | 16.29 | 0.12 |
| Director sitting fees | 7.68 | 0.83 |
| Miscellaneous expenses | 3.37 | 3.50 |
| 5/ 08/8000000000000000000000000000000000 | 1,469.44 | 1,037,39 |

* Auditors' remuneration (excluding Goods and services tax)

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Statutory audit fees | 11.42 | 4.40 |
| Certification fees | 0.90 | 0.10 |
| Other services (included in Legal and professional) | | 7.10 |
| | 12.32 | 11.60 |

^{**} Represents lease rentals for short term leases and leases of low value assets





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

27 Contingent liabilities and commitments

| Particulars | As at 31 March 2022 | As a |
|--|------------------------|--------------|
| Contingent liabilities: | 31 March 2022 | 31 March 202 |
| Bonus as per The Payment of Bonus (Amendment) Act, 2015 for the period from 1 April 2014 to 31 March 2015 (Refer note a) | 6.15 | 6.15 |
| i) Demands raised by income-tax authorities for assessment years 2017-18 on account of disallowance of amortisation on goodwill and prior period expenditure and disallowance u/s 14A to the extent applicable [Amount paid to Income tax authority under protest of Rs. 8.02 million (31 March 2021: 8.02 million)] | 22.46 | 20.75 |
| i) Disallowance of Employee stock option expenses and disallowance under section 14A for assessment year 2017-18 | 3.74 | 3.74 |
| Demand raised by Income tax authorities for assessment years 2018-19 on account of disallowance of amortization of intangible assets | 30.67 | |
| v) Disallowance of Employee stock option expenses and disallowance under section 14A for assessment year 2018-19 | 0.78 | |
| i) Disallowed u/s 40(a)(ia) of the Income-tax Act, 1961, for payments made to various hospitals during the financial year 2007-08 and 2008-09 (Refer note b) | 464.96 | 464.96 |
| i) Bank guarantee | 180.83 | 180.83 |
| Commitments: | | |
| Estimated amount of contracts, remaining to be executed on capital account and not provided for | 20.26 | 40.20 |

Notes:

- (a) The Payment of Bonus (Amendment) Act, 2015 was notified by the Government of India with retrospective effect from 1 April 2014. The Honorable High Court, Karnataka based on the writ Petition no 5272/2016 and 5311/2016, has vide its order dated 2 February 2016, stayed the operation of the said notification for the financial year 2014-15. The obligation to pay the Bonus for the financial year 2014-15 will arise only if the High Court disposes off the writ petition in favour of the Government. Hence, the Company has taken a view that an amount of Rs 6.15 million which is the approximate statutory bonus liability, for the eligible employees in respect of financial year 2014-15, has been considered as an contingent liability.
- (b) As per Income tax assessment order, the Assessing Officer has disallowed u/s 40(a)(ia) on payments made to various hospitals during the financial year 2007-08 and 2008-09 totaling to Rs 118.92 million Rs 964.75 million respectively and accordingly raised a demand of Rs. 29.71 million and Rs. 435.25 million u/s 143(3) of the IT Act respectively against Dedicated Healthcare Services TPA (India) Private Limited (DHS). DHS filed an appeal against these above Orders as the payments to hospitals were made from the funds received from insurance companies were an advance and all payments were adjusted against the advance received. The payments were not claimed as an expenditure, hence, these cannot be disallowed under said section. The DHS received favorable orders from CIT(A) on 8 August 2012, ITAT on 10 December 2014, and the High Court on 30 November 2015. However, the IT department has filed an appeal with The Honorable Supreme Court of India. Further, the subsidiary company had acquired DHS on dated 30 September 2016 and pursuant to the merger order dated 6 April 2018, DHS merged with the subsidiary company from the appointed date specified in the Scheme i.e. 1 October 2016.
- (c) In light of judgment of Honorable Supreme Court dated 28 February 2019 on the definition of "Basic Wages" under the Employees Provident Funds & Misc. Provisions Act, 1952 and based on Group evaluation, there are significant uncertainties and numerous interpretative issues relating to the judgement and hence, it is unclear as to whether the clarified definition of Basic Wages would be applicable prospectively or retrospectively. The amount of the obligation therefore cannot be measured with sufficient reliability for past periods. The Group will evaluate its position and update its provision, if required, on receiving further clarity on the subject. The Group does not expect any material impact of the same.





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions except share data and per share data, unless otherwise stated)

28 Earnings per share

| Particulars | Note | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|--|-----------|-------------------------------------|-------------------------------------|
| Profit attributable to ordinary shareholders | | | |
| Net profit for the year attributable to the equity share holders from continuing operations | (a) | 634.67 | 380.06 |
| Net (loss) for the year attributable to the equity share holders from discontinued operation | (b) | 7.51 | (117.31) |
| Weighted average number of equity shares outstanding for basic EPS | (c)* | 68,859,212 | 66,973,876 |
| Weighted average number of equity shares outstanding for diluted EPS | (d)** | 69,435,773 | 67,652,946 |
| Earnings per equity share | | | |
| Basic earning per share of Rs 5 each (for continuing operation) | [a/c] | 9.22 | 5.67 |
| Diluted earning per share of Rs 5 each (for continuing operation) | [a/d] | 9.14 | 5.62 |
| Basic earning per share of Rs 5 each (for discontinued operation) | [b/c] | 0.11 | (1.75) |
| Diluted earning per share of Rs 5 each (for discontinued operation) | [b/d] | 0.11 | (1.75) |
| Basic earning per share of Rs 5 each (for continuing and discontinued operation) | [(a+b)/c] | 9.33 | 3.92 |
| Diluted earning per share of Rs 5 each (for continuing and discontinued operation) | [(a+b)/d] | 9.25 | 3.88 |

* Computation of weighted average number of equity shares used in calculating basic earning per share is set out below:

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Opening balance | 36,082 | 36,082 |
| Conversion of Redeemable Preference share into CCPS and thereafter Equity (Refer Note 14(a)) | 1,099 | 81 |
| Capitalization due to share split from paid-up capital of Rs.10 per equity share to Rs. 5 per equity share (Refer Note 1 below) | -, | *** |
| | 37,181 | 36,163 |
| Capitalization of bonus shares issued (925 Bonus share issued per equity share) (Refer Note 1 below) | 68,784,850 | 66,901,550 |
| Weighted average number of equity shares | 68,859,212 | 66,973,876 |

1. Pursuant to a resolution passed by the Shareholders on 7 April 2021 and subsequent allotment on 9 April 2021, the Company has sub-divided the face value of its equity shares from Rs. 10 each to Rs. 5 each. Further, the Company has allotted 68,784,850 equity shares of face value of Rs. 5 each by way of bonus issue to its shareholders and consequently the paid-up share capital of the Company has been increased to 68,859,212 equity shares of face value of Rs. 5 each and the Board authorised for appropriate adjustments on allotment of share split and bonus shares to the outstanding options granted to the employees under the ESOP scheme.

** Computation of weighted average number of equity shares used in calculating diluted earning per share is set out below:

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Weighted average number of equity shares outstanding during the period for calculating basic EPS Effect of dilutive potential equity shares: | 68,859,212 | 66,973,876 |
| Employee stock options | 576,561 | 679,070 |
| Weighted average number of equity shares | 69,435,773 | 67,652,946 |

ASSOCIATES *





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued) (All amounts are in Indian Rupees in millions, unless otherwise stated)

29 Additional information pursuant to paragraph 2 of Division II of Schedule III to the Companies Act, 2013 'General instructions for the preparation of Consolidated financial statements

As of 31 March 2022

| Name of the entity | Net Assets | | Share in profit or loss | loss | Share in OCI | | Share in total compreher | sive income |
|--|---------------|----------|-------------------------|--------|---------------|---------|--------------------------|-------------|
| Common and the common | As % of total | Amount | As % of total | Amount | As % of total | Amount | As % of total | Amount |
| Parent Medi Assist Healthcare Services Limited | 49.15% | 1,671.23 | 28.83% | 184.97 | 24.29% | (6.25) | 29.02% | 178.72 |
| Subsidiary Medi Assist Insurance TPA Private Limited | \$0.85% | 1,729.07 | 71.17% | 456.69 | 75.71% | (19.48) | 70.98% | 437.21 |
| | 100.00% | 3,400.30 | 100.00% | 641.66 | 100.00% | (25.73) | 100.00% | 615.93 |

As of 31 March 2021

| Name of the entity | Net Assets | | Share in profit or loss | · loss | Share in OCI | | Share in total comprehensive in | nsive income |
|--|---------------|----------|-------------------------|----------|---------------|--------|---------------------------------|--------------|
| farmer on the country | As % of total | Amount | As % of total | Amount | As % of total | Amount | As % of total | Amount |
| Parent Medi Assist Healthcare Services Limited | 39.85% | 1,165.73 | -148.39% | (389.89) | 202.43% | 8.32 | -142.99% | (381.57) |
| Subsidiary Medi Assist Insurance TPA Private Limited | 60.15% | 1,759.77 | 248.39% | 652.63 | -102.43% | (4.21) | 242.99% | 648.42 |
| | 100.00% | 2,925.50 | 100.00% | 262.74 | 100.00% | 4.11 | 100.00% | 266.85 |





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

30 Employee benefits

The Group contributes to the following post-employment plans.

a) Defined contribution plan:

The contributions paid/ payable to Employee Provident Fund, Employees State Insurance Scheme ("ESI"), Employees Pension Schemes, 1995 and other funds, are determined under the relevant approved schemes and/or statutes and are recognised as expense in the statement of profit and loss during the year in which the employee renders the related service. There are no further obligations other than the contributions payable to the approved trusts/appropriate authorities.

The Group makes contributions, determined as a specified percentage of employees salaries, in respect of qualifying employees towards provident fund and employees state insurance, which are defined contribution plans. The Group has no obligation other than to make the specified contribution. The contributions are charged to the statement of profit and loss as they accrue. The amount recognized as an expense towards contribution to provident fund and employee state insurance for the year amounts to Rs. 75.03 million (31 March 2021: Rs. 80.48 million)

b) Defined benefit plans:

The Group has a defined benefit gratuity plan governed by the Payment of Gratuity Act, 1972. The plan entitles an employee who has rendered atleast five years of continuous service to receive 15 days salary for every completed year of service or part thereof in excess of six months based on the rate of last drawn salary (basic plus dearness allowance) by the employee concerned. The Group's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial gains/ (losses) are recognised under other comprehensive income in the Statement of profit and loss.

The Group has considered only such changes in legislation which have been enacted upto the Balance sheet date for the purpose of determining defined benefit obligation

Based on the actuarial valuation obtained in this respect, the following table sets out the details of the employee benefit obligation and the plan assets as at balance sheet date:

| Particulars | As at | As at |
|--------------------------------|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Defined benefit obligation | 159.52 | 121.45 |
| Fair value of plan assets | (6.68) | (7.69) |
| Net defined benefit obligation | 152.84 | 113.76 |
| Current liabilities | 40.62 | 28.18 |
| Non-current liabilities | 112.21 | 85.56 |

I Movement in net defined benefit liability

Reconciliation of present value of defined benefit obligation

| Particulars | As at | As at |
|---|---------------|---------------|
| Dalance at the best size of the | 31 March 2022 | 31 March 2021 |
| Balance at the beginning of the year | 121.45 | 105.89 |
| Benefits paid | (16.17) | (14.31) |
| Current service cost | 22.29 | 17.30 |
| Past service cost | ***** | |
| Interest cost | | 2.75 |
| | 5.39 | 5.40 |
| Actuarial gains/(losses) recognised in other comprehensive income | | |
| Changes in demographic assumptions | | 1.85 |
| Changes in financial assumptions | (1.80) | |
| Experience adjustment | (1.89) | 0.88 |
| Effect of acquisition/ (divestiture) | 30.09 | 1.69 |
| | (1.64) | 4 |
| Balance at the end of the year | 159.52 | 121.45 |

Reconciliation of present value of plan assets

| Particulars | As at | As at |
|---|-------------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Balance at the beginning of the year | (7.69) | (7.85) |
| Addition on business combination | | 4,775 |
| Contributions paid by the employer | (14.73) | (14.71) |
| Benefits paid | | 1,750,000,000 |
| Interest income | 16.17 | 14.31 |
| | (0.29) | (0.41) |
| Return on planned assets recognised in other comprehensive income | 040 <u>4</u> 0000 | 200 |
| Re-measurements on Plan Assets - Loss/ (Gain) | 5* | |
| Experience adjustment | (0.16) | 0.74 |
| | 0.02 | 0.23 |
| Balance at the end of the year | (6,68) | (7.69) |

Expense recognised in statement of profit and loss

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|----------------------|-------------------------------------|-------------------------------------|
| Current service cost | 22,29 | 17.30 |
| Past service cost | | 2.75 |
| Interest cost | 5.39 | 5.40 |
| Interest income | (0.29) | (0.41) |
| | 27.39 | 25.04 |

Expense recognised in other comprehensive income

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|---|-------------------------------------|-------------------------------------|
| Changes in demographic assumptions | | 1.85 |
| Changes in financial assumptions | (1.89) | 0.88 |
| Experience adjustment | 30.09 | 1.69 |
| Re-measurements on Plan Assets - Gain/ (loss) | (0.16) | 0.74 |
| R ACCOC | 28.04 | 5.16 |



Notes to Consolidated financial statements (continued)

Medi Assist Healthcare Services Limited

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

30 Employee benefits (continued)

II. Plan assets

Plan assets comprise the following

| Particulars | As at | As at |
|---|---------------|---------------|
| | 31 March 2022 | 31 March 2021 |
| Managed by - Reliance Nippon Life Insurance and LIC Limited - 100% funded | 6.69 | 7.72 |
| | 6.69 | 7.72 |

iii. Actuarial assumptions

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages).

| Particulars | As at | As at |
|---------------------------|------------------|------------------|
| | 31 March 2022 | 31 March 2021 |
| Discount rate | 4,90% | 4.50% |
| Expected return | | |
| Future salary growth | 4.50% | 5.10% |
| | 8.00% | 8.00% |
| Mortality | IALM 2012-14 Uit | IALM 2012-14 Ult |
| Rate of employee turnover | 37% | 35% - 37% |

iv. Sensitivity analysis

| Particulars | As at 31 March 2022 | | As at 31 March 2021 | |
|---|---------------------|----------|---------------------|----------|
| B) ON | Increase | Decrease | Increase | Decrease |
| Discount rate (1% movement) | (4.60) | 4.82 | (3.57) | 3.78 |
| Future salary growth (1% movement) | 4.64 | (4.51) | 3.62 | (3.48) |
| Rate of employee turnover (1% movement) | (0.85) | 0.89 | (0.75) | 0.79 |

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

v. Expected future cash flows

| Particulars | As at 31 Marc | As at 31 March 2022 | | 2021 |
|--------------------------------|---------------|---------------------|------------|--------------|
| | Discounted | Undiscounted | Discounted | Undiscounted |
| 1# Following year | 59,99 | 61.44 | 43.18 | 44,14 |
| 2 nd Following year | 48.33 | 51.92 | 34.30 | 36.64 |
| 3 rd Following year | 37.44 | 42.20 | 27.55 | 30.75 |
| 4th Following year | 31.08 | 36.75 | 23.12 | 26.97 |
| 5th Following year | 24.15 | 29.95 | 19.14 | 23.33 |
| Thereafter | 51.83 | 72.16 | 40.84 | 55.51 |

vi. Description of Risk Exposures:

Valuations are based on certain assumptions, which are dynamic in nature and vary over time. As such Group is exposed to various risks as follow -

- a) Salary Increases- Actual salary increases will increase the Plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.
- b) Investment Risk- If plan is funded then assets liabilities mismatch and actual investment return on assets lower than the discount rate assumed at the last valuation date can impact the liability.
- Discount Rate- Reduction in discount rate in subsequent valuations can increase the plan's liability.
- d) Mortality- Actual deaths & disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
- e) Withdrawals- Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact Plan's liability.

(c) Other long-term employee benefits:

The Group provides for compensated absences to its employees. The employees can carry-forward a portion of the unutilised accrued compensated absences and utilise it in future service years. During the year ended 31 March 2022, the Group has incurred an expense on compensated absences amounting to Rs. (0.69) million [31 March 2021: Rs. 1.30 million]. The Group determines the expense for compensated absences basis the actuarial valuation of the present value of the obligation, using the Projected Unit Credit Method.







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

31 Employee stock option scheme

31 (a) 2013 plan

The Company has established Employee Stock Option Scheme 2013 ("ESOS 2013") with effect from 1 October 2013 to enable the employees of the Company to participate in the future growth and success of the Company. ESOS 2013 is operated at the discretion of the Board of directors.

These options which confer a right but not an obligation on the employee to apply for equity shares of the Company once the terms and conditions set forth in the Employee Stock Option Scheme 2013 ("ESOS 2013") and the option agreement have been met. Vesting of options would be subject to continued employment with the Company and meeting the requisite performance parameters.

The Company had below share based payment arrangement under ESOS 2013 as on 31 March 2022

| Particulars | Date of grants | Number of option granted | Exercise price (in Rs) |
|-------------|----------------|--------------------------|---------------------------|
| Grant I | 1-Oct-13 | 108 | 66,603 |
| Grant II | 1-Sep-15 | 254 | 407,275 |
| Grant III | 5-Sep-18 | 29 | 339,213 |
| Grant IV | 1-Jul-21 | 1,301,956 | 256 |

Conditions:

Vesting condition Exercise period Method of settlement

Continued employment with the Company and fulfilment of performance parameters

Exercise on listing / strategic sale

Equity

Vesting period

| Grant I | Grant II | Crant III | C 171 |
|---------|------------------|--|---|
| | | THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TW | Grant IV |
| | | 100% | 10% |
| 50% | 25% | 0% | 20% |
| 25% | 25% | 0% | 20% 30% |
| 25% | | | 40% |
| | 0% 50% 25% | 0% 50% 50% 25% 25% 25% | 0% 50% 100% 50% 25% 0% 25% 25% 0% |

Modification of Employee stock option scheme

The Company has made capital restructuring by way of right issues to existing shareholder. In accordance with the "ESOS 2013" scheme, non-discretionary anti-dilution provisions exists. Resulting in terms of modification of the scheme, there by additional options have been given to option grantees by the company. Due to existence of non-discretionary provision this has not resulted in any incremental share based payment expense reason being the fair value of the options immediately before and after the rights issue were same.

| Particulars | Grant I | Grant II |
|------------------------|---------|----------|
| Revised exercise price | 32,696 | 199,877 |
| Additional ESOS issued | 112 | 265 |
| Revised ESOS in force | 220 | 519 |

Reconciliation of outstanding share options:

For the year ended 31 March 2022

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|---|--|--|---|---|
| Outstanding as at 1 April 2021 (refer note 14(a)) | 1,211,208 | 256 | 256 | |
| Add: Options granted during the year | 1,301,956 | 256 | 256 | 4.00 |
| Less: Options lapsed during the year | 172,236 | 230 | 236 | 4.00 |
| Options outstanding at 31 March 2022 | 2,340,928 | 256 | 256 | 400 |
| Exercisable options at 31 March 2022 | The state of the s | The state of the s | | 4.00 |
| - Production and Production 2022 | 1,211,208 | 256 | 256 | 4.00 |

For the year ended 31 March 2021

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|---|--|--|---|---|
| Outstanding as at 1 April 2020 | 654 | 32,696 to 339,213 | 178,959 | 3.00 |
| Less: Options lapsed during the year | | | 170,555 | 3.00 |
| Less: Options exercised during the year | | 2 | - | ** |
| Options outstanding at 31 March 2021 | 654 | 32,696 to 339,213 | 178,959 | |
| Exercisable options at 31 March 2021 | The state of the s | The second secon | | 3.50 |
| Promo me De tranten aval | 654 | 32,696 to 339,213 | 178,959 | 3.5 |

Valuation of stock option

Options have been valued based on fair value method as described under Ind AS 102 Share based payments, using Black Scholes valuation options pricing model, by using the fair value of the company's shares on the grant date.

| Particulars | Grant I | Grant II | Grant III | Grant IV |
|---|----------|----------|-----------|---------------|
| Grant date | 1-Oct-13 | 1-Sep-15 | 5-Sep-18 | |
| Share price in Rs | 316,032 | 407,275 | 339,213 | 1-Jul-21 |
| Exercise price in Rs | 66,603 | 407,275 | 339,213 | 257 |
| Expected volatility | 27.50% | 27.50% | 26.37% | 256 33.75% |
| Expected life | 5,42 | 4.50 | 2.57 | 4.00 |
| Dividend yield | 0% | 0% | 0% | 4.00 |
| Risk-free interest rate (based on government bonds) | 8.82% | 7.79% | 7.80% | 5.24% |
| Fair value in Rs | 274,744 | 153,254 | 88,004 | 81.07 |

Expenses summary of shared-based payment

For details on employee benefit expenses refer Note 23.







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

31 Employee stock option scheme

31 (a) 2013 plan

The Company has established Employee Stock Option Scheme 2013 ("ESOS 2013") with effect from 1 October 2013 to enable the employees of the Company to participate in the future growth and success of the Company. ESOS 2013 is operated at the discretion of the Board of directors.

These options which confer a right but not an obligation on the employee to apply for equity shares of the Company once the terms and conditions set forth in the Employee Stock Option Scheme 2013 ("ESOS 2013") and the option agreement have been met. Vesting of options would be subject to continued employment with the Company and meeting the requisite performance parameters.

The Company had below share based payment arrangement under ESOS 2013 as on 31 March 2022

| Particulars | Date of grants | Number of option granted | Exercise price (in Rs) |
|-------------|----------------|--------------------------|---------------------------|
| Grant I | 1-Oct-13 | 108 | 66,603 |
| Grant II | 1-Sep-15 | 254 | 407,275 |
| Grant III | 5-Sep-18 | 29 | 339,213 |
| Grant IV | 1-Jul-21 | 1,301,956 | 256 |

Conditions:

Vesting condition Exercise period Method of settlement Continued employment with the Company and fulfilment of performance parameters

Exercise on listing / strategic sale

Emity

Vesting period

| Particulars | Grant I | Grant II | Grant III | Grant IV |
|--------------------------|---------|----------|-----------|----------|
| At the end of one year | 0% | 50% | 100% | 10% |
| At the end of two year | 50% | 25% | 0% | 20% |
| At the end of three year | 25% | 25% | 0% | 30% |
| At the end of four year | 25% | 0% | 0% | 40% |

Modification of Employee stock option scheme

The Company has made capital restructuring by way of right issues to existing shareholder. In accordance with the "ESOS 2013" scheme, non-discretionary anti-dilution provisions exists. Resulting in terms of modification of the scheme, there by additional options have been given to option grantees by the company. Due to existence of non-discretionary provision this has not resulted in any incremental share based payment expense reason being the fair value of the options immediately before and after the rights issue were same.

| Particulars | Grant I | Grant II |
|------------------------|---------|----------|
| Revised exercise price | 32,696 | 199,877 |
| Additional ESOS issued | 112 | 265 |
| Revised ESOS in force | 220 | 519 |

Reconciliation of outstanding share options:

For the year ended 31 March 2022

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|---|-------------------------------|--------------------------------------|---|---|
| Outstanding as at 1 April 2021 (refer note 14(a)) | 1,211,208 | 256 | 256 | |
| Add: Options granted during the year | 1,301,956 | 256 | 256 | 4.00 |
| Less: Options lapsed during the year | 172,236 | | | |
| Options outstanding at 31 March 2022 | 2,340,928 | 256 | 256 | 4.00 |
| Exercisable options at 31 March 2022 | 1,211,208 | 256 | 256 | 4.00 |

For the year ended 31 March 2021

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|---|-------------------------------|--------------------------------------|---|---|
| Outstanding as at 1 April 2020 | 654 | 32,696 to 339,213 | 178,959 | 3.00 |
| Less: Options lapsed during the year | | | | |
| Less: Options exercised during the year | | 2 1 | | |
| Options outstanding at 31 March 2021 | 654 | 32,696 to 339,213 | 178,959 | 3.50 |
| Exercisable options at 31 March 2021 | 654 | 32,696 to 339,213 | 178,959 | 3.50 |

Valuation of stock option

Options have been valued based on fair value method as described under Ind AS 102 Share based payments, using Black Scholes valuation options pricing model, by using the fair value of the company's shares on the grant date.

| Particulars | Grant I | Grant II | Grant III | Grant IV |
|---|----------|----------|-----------|----------|
| Grant date | 1-Oct-13 | 1-Sep-15 | 5-Sep-18 | 1-Jul-21 |
| Share price in Rs | 316,032 | 407,275 | 339,213 | 257 |
| Exercise price in Rs | 256 | 407,275 | 339,213 | 256 |
| Expected volatility | 27.50% | 27.50% | 26.37% | 33.75% |
| Expected life | 5.42 | 4.50 | 2.57 | 4.00 |
| Dividend yield | 0% | 0% | 0% | 1% |
| Risk-free interest rate (based on government bonds) | 8.82% | 7.79% | 7,80% | 5.24% |
| Fair value in Rs | 274,744 | 153,254 | 88,004 | 81.07 |

Expenses summary of shared-based payment

For details on employee benefit expenses refer Note 23.





Notes to Consolidated financial statements (continued) (All amounts are in Indian Rupees in millions, unless otherwise stated)

31 (b) Employee stock option scheme of subsidiary:

Medi Assist Insurance TPA Private Limited

2012 plan

The Company has introduced Employee Stock Option Scheme 2012 ("ESOS 2012") with effect from 30 April 2012 to enable the employees of the Company to participate in the future growth and success of the Company. ESOS 2012 is operated at the discretion of the Board.

The Company has granted to its employee 87,842 employee stock options on 30 April 2012, 17,333 employee stock options on 30 April 2013, 28,198 employee stock options on 1 June 2014, 6,374 employee stock options on 1 June 2015, 13,500 employee stock options on 15 September 2015, 29,000 employee stock options on 15 July 2016 and 45,394 employee stock options on 1 July 2017. These options which confer a right but not an obligation on the employee to apply for equity shares of the Company once the terms and conditions set forth in the Employee Stock Option Scheme 2012 ("ESOS 2012") and the option agreement have been met. Vesting of options would be subject to continued employment with the Company and meeting the requisite performance parameters. As at the balance sheet date 86,257 options were vested to the employees.

The Company had below share based payment arrangement under ESOS 2012 as on 31 March 2022

| Particulars | Date of grants | Number of option granted | Exercise price |
|-------------|----------------|--------------------------|----------------|
| Grant I | 30-Apr-12 | 45,400 | 140 |
| Grant II | 30-Apr-12 | 40,124 | 140 |
| Grant III | 30-Apr-12 | 2,318 | 140 |
| Grant IV | 30-Apr-13 | 17,333 | 235 |
| Grant V | 1-Jun-14 | 28,198 | 966 |
| Grant VI | 1-Jun-15 | 6,374 | 1,244 |
| Grant VII | 15-Sep-15 | 13,500 | 1,244 |
| Grant VIII | 15-Jul-16 | 29,000 | 1,368 |
| Grant IX | 1-Jul-17 | 18,110 | 1,505 |
| Grant X | 1-Jul-17 | 15,405 | 1,505 |
| Grant XI | 1-Jul-17 | 7,434 | 1,505 |
| Grant XII | 1-Jul-17 | 4,445 | 1,505 |

Conditions

Vesting condition Exercise period Method of settlement

Continued employment with the Company and fulfillment of performance parameters Exercise on listing / strategic sale

Equity

Vesting schedule

| | Grant I | Grant II | Grant III | Grant IV, V, VI, VII, VIII and IX |
|----------------------|---------|----------|-----------|--------------------------------------|
| At the end of 1 year | 15% | 33% | 100% | 15% |
| At the end of 2 year | 20% | 33% | | 20% |
| At the end of 3 year | 30% | 34% | | 30% |
| At the end of 4 year | 35% | | * | 35% |

| | Grant X | Grant XI | Grant XII |
|----------------------|---------|----------|-----------|
| At the end of 1 year | 35% | 65% | 100% |
| At the end of 2 year | 30% | 35% | 0% |
| At the end of 3 year | 35% | 0% | 0% |
| At the end of 4 year | 0% | 0% | 0% |

Modified Vesting schedule

| - | Grant I | Grant II | Grant III | Grant IV, V, VI, VII, VIII and IX |
|-----------|---------|----------|-----------|--------------------------------------|
| Immediate | 100% | 100% | 100% | 100% |

| | Grant X | Grant XI | Grant XII |
|-----------|---------|----------|-----------|
| Immediate | 100% | 100% | 100% |

Fair value of options Pre and Post modification:

(Amount in Rs.) Particulars

| | | Date of grants | Modification | Fair Value Post Modification |
|------------|---------------|---------------------|--------------|---------------------------------|
| Grant I | | 30-Apr-12 | 2,160 | 2,139 |
| Grant II | | 30-Apr-12 | 2,160 | 2,139 |
| Grant III | | 30-Apr-12 | 2,160 | 2,139 |
| Grant IV | | 30-Apr-13 | 2,085 | 2,049 |
| Grant V | ASSO | 1-Jun-14 | 1,512 | 1,363 |
| Grant VI | S TOO C | 1-Jun-15 | 1,295 | 1,103 |
| Grant VII | 134 | 15-Sep-15 | 1,296 | 1,103 |
| Grant VIII | 100 | 15-Jul-16 | 1,224 | 986 |
| Grant IX | +MCAV - 1 + 1 | 1-Jul-17 | 1,174 | 858 |
| Grant X | 1/9/ /2// | 1-Jul-17 | 1,123 | 858 |
| Grant XI | 5 | lealthcare 1-Jul-17 | 1,096 | 858 |
| Grant XII | red Account | 1-Jul-17 | 1,096 | 858 |

Fair market value as on the date of modification Rs. 2,270 per option.



Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

Reconciliation of outstanding employee stock options:

31 (b) Employee stock option scheme of subsidiary (continued)

For the year ended 31 March 2022

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|---|-------------------------------|--------------------------------------|---|---|
| Outstanding as at 1 April 2021 | 86,257 | 140 - 1,505 | 709 | 1.00 |
| Add: Options granted during the year | 2000 | | | * |
| Less: Options lapsed during the year | | | | |
| Options outstanding as at 31 March 2022 | 86,257 | 140 - 1,505 | 709 | 1.00 |
| Exercisable as at 31 March 2022 | 86,257 | 140 - 1,505 | 709 | 1.00 |

For the year ended 31 March 2021

| Particulars | Shares arising out of options | Range of exercise prices (in Rs.) | Weighted average exercise price (in Rs.) | Weighted average remaining contractual life |
|--------------------------------------|-------------------------------|--------------------------------------|---|---|
| Outstanding as at 1 April 2020 | 86,257 | 140 - 1,505 | 709 | 1.00 |
| Add: Options granted during the year | | 2 | - | |
| Less: Options lapsed during the year | | | - 1 | |
| Options outstanding at 31 March 2021 | 86,257 | 140 - 1,505 | 709 | 1.00 |
| Exercisable options at 31 March 2021 | 86,257 | 140 - 1,505 | 709 | 1.00 |

Expenses summary of shared-based payment For details on employee benefit expenses refer Note 23.





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued) (All amounts are in Indian Rupees in millions, unless otherwise stated)

32 Financial instruments - Fair values and risk management

A. Accounting classification and fair values

Carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy are presented below, other than those with carrying amounts that are reasonable approximations of fair values"

As at 31 March 2022

| Particulare | | Carrying amount | mount | | | Fair value | | |
|---|----------|-----------------|----------------|----------|----------|------------|---------|----------|
| | FVTPL | FVOCI | Amortised cost | Total | Lovel 1 | I ovel 3 | | |
| Financial assets | | | | | | 7 13437 | C ISAST | Local |
| Non-current | | | | | | | | |
| Non-current investments | 1 | 66.39 | r | 66'39 | 13.96 | | 55.43 | 66 30 |
| Other Imancial assets | | ٠ | 34,05 | 34.05 | , | * | | |
| Current | | | | | | | | |
| Investments | 1,945.04 | ż | | 1,945,04 | 1 945 04 | | | 1 045 04 |
| Trade receivables | * | • | 1.187.70 | 1.187.70 | | | | 1,745.04 |
| Cash and cash equivalents | | 2 | 145.95 | 145.95 | 28 | | | 1 |
| Bank balances other than cash and cash equivalents | | | 479.38 | 479.38 | × | | | |
| Other financial assets | , | , | 249.11 | 249.11 | | , | | |
| | 1,945.04 | 66.39 | 2,096.19 | 4,110.62 | 1,959.00 | | 55.43 | 2,014.43 |
| Financial liabilities Non-current Lease liabilities | | | 175.20 | 175.20 | • | * | | |
| Current Lease liabilities | | | 99.58 | 99.58 | | | , | , |
| Trade and other payables | K | (6) | 290.20 | 290.20 | | | , | |
| Other financial liabilities | | | 91.55 | 91.55 | | | , | 200 |
| 1 | | | 656.53 | 656.53 | | | | |





Medi Assist Healthcare Services Limited
Notes to Consolidated financial statements (continued)
(All amounts are in Indian Rupees in millions, unless otherwise stated)

As at 31 March 2021

| Particulars Carrying amount Fair value Fair value Financial assets FVIPL FVOCI Amortised cost Total Level 1 Level 2 Level 3 TA Non-current investments Non-current investments TAT2 42.99 42.99 42.99 1.030.89 | AS AUGI MATCH 2021 | | | | | | | | (Rs in millions) |
|--|--|----------|------------|----------------|----------|----------|-----------|-------|------------------|
| FYTPL FVOCI Amortised cost Total Level 1 Level 2 Level 3 1,030.89 | Particulars | | Carrying a | mount | | | Fair valu | 9 | |
| 1,030.89 | | FVTPL | FVOCI | Amortised cost | Total | Level 1 | Level 2 | | Total |
| 1,030.89 - 1,030.89 | Financial assets | | | | | | | | 10101 |
| s cash and cash equivalents 1,030.89 | Non-current | | | | | | | | |
| s cash and cash equivalents 1,030.89 | Non-current investments | * | 74.72 | • | 74.72 | 19.29 | | 55.43 | 74 77 |
| s cash and cash equivalents | Other financial assets | | • | 42.99 | 42.99 | , | , | , | 1 |
| 1,030.89 | Current | | | | | | | | |
| cash and cash equivalents - 1,210.80 1,210.80 - 633.89 633.89 - 633.89 633.89 - 633. | Investments | 1,030.89 | , | • | 1,030.89 | 1,030.89 | , | ٠ | 1,030.89 |
| cash and cash equivalents - 633.89 633.89 633.89 513.45 513.45 192.56 192.56 192.56 192.56 659.30 1,050.18 - 55.43 1 1 | Trade receivables | | 25 | 1,210.80 | 1,210.80 | | | | |
| cash and cash equivalents 1,030.89 74.72 2,593.69 3,699.30 1,050.18 | Cash and cash equivalents | | | 633.89 | 633.89 | | | • | , |
| 1,030.89 74.72 2,593.69 3,699.30 1,050.18 - 55.43 1 256.76 256.76 256.76 - - - - - 96.24 96.24 - - - - 173.72 173.72 - - - 861.60 861.60 861.60 - - | Bank balances other than cash and cash equivalents | 50 | 10 | 513.45 | 513.45 | 3. | | • | |
| 1,030.89 74.72 2,593.69 3,699.30 1,050.18 - 55.43 1 - 256.76 256.76 - - - - - 96.24 96.24 - - - - 334.88 334.88 - - - 173.72 173.72 - - - 861.60 861.60 - - | Other financial assets | | | 192.56 | 192.56 | * | 35 | | • |
| 256.76 256.76 96.24 96.24 334.88 334.88 861.60 861.60 | | 1,030.89 | 74.72 | 2,593.69 | 3,699,30 | 1,050.18 | | 55.43 | 1.105.61 |
| 256.76 - 96.24 - 334.88 - 173.72 - 861.60 | Financial liabilities | | | | | | | | |
| 256.76 96.24 334.88 - 173.72 | Non-current | | | | | | | | |
| 96.24 334.88 - 173.72 | Lease liabilities | ž | 7 | 256.76 | 256.76 |))* | 31. | ı | , |
| 96.24 334.88 - 173.72 | Current | | | | | | | | |
| . 334.88 | Lease liabilities | 38 | 31 | 96.24 | 96.24 | | | , | |
| 173.72 | Frade and other payables | × | .* | 334.88 | 334.88 | . , | | | (a) % |
| | Other financial liabilities | | | 173.72 | 173.72 | | | | |
| | | | | 861.60 | 861.60 | | 3. | | , |





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

B. Measurement of fair values

The following methods and assumptions were used to estimate the fair values:

- a) The fair values of the units of mutual fund schemes are based on net asset value at the reporting date.
- c) All other financial assets except mutual funds and financial liabilities are recognised at amortised cost. Hence, there are no financial assets/ liabilities classified under Level 2 and Level 3. b) The fair values of the equity shares invested in The New India Assurance Co Ltd' is as per the closing market price at the reporting date

Reconciliation of fair value measurement of non-current investments being classified as FVTPL/FVOCI (Level 3);

| Particulars | Investment in financial assets |
|--|-----------------------------------|
| Opening balance as on 1 April 2020 | 13831 |
| Addition during the year | 050 |
| Deletion during the year | (138 48) |
| Fair value movement recognised in statement of profit and loss | 46.43 |
| Fair value movement recognised in other comprehensive income | 8 67 |
| Closing balance as on 31 March 2021 | 55.43 |
| Opening balance as on I April 2021 | 55.43 |
| Addition during the year | Ctron |
| Deletion during the year | 0.1 |
| and an aming man dear | • |
| Fair value movement recognised in statement of profit and loss | |
| Fair value movement recognised in other comprehensive income | |
| Closing balance as on 31 March 2022 | 55.43 |

A one percentage change in the unobservable inputs used in the fair valuation of level 3 assets does not have a significant impact in the fair value of the financial instrument. There have been no transfers among Level 1, Level 2 and Level 3 during the year ended 31 March 2022.

Description of significant unobservable inputs to valuation:

| ne of financial asset | Valuation technique Signi | ignificant unobservable inputs |
|--|--|---|
| stricent in unquoted equity shares and preference shares | Discounted cash flow method was used to capture the present value of the expected Long term growth rate future economic benefits that will flow to the Company arising from the investments Discount rate in financial assets. | g term growth rate count rate enue multiple |

These investments in unquoted equity shares and preference shares are carried at fair value based on recent round of funding received by investee companies.





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

32 Financial instruments - Fair values and risk management (continued)

C. Financial risk management

Risk management framework

The Group's management has overall responsibility for the establishment and oversight of the risk management framework.

The Group's management monitors compliance with the risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The management is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad-hoc reviews of risk management controls and procedures, the results of which are reported to the management.

Management assessment of recoverability of trade receivables: During the year, the Group carried out a detailed customer-wise assessment of the recoverability of the trade receivables. Basis that assessment, the group has created a provision for expected credit loss on trade receivables which the management considers as adequate

The Group has exposure to the following risks arising from financial instruments:

- Market risk;
- Credit risk; and
- Liquidity risk

i. Market risk

Market risk is the risk that changes in market prices - such as interest rates and equity prices - will affect the company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return. Material investments within the portfolio are managed on an individual basis and all buy and sell decisions are approved by the appropriate authority. The Group's fixed rate fixed deposit are carried at amortised cost. They are therefore not subject to interest rate risk as defined in Ind AS 107, since neither the carrying amount nor the future cash flows will fluctuate because of a changes in market interest rates.

The Group's borrowings are at fixed rate of interest and therefore any change in the base interest rate will not have any impact of Consolidated Financial Statements.

Currency risk

The Group primarily renders services and avails goods and services in domestic currency i.e. Indian rupees. Hence, no exposure to currency risk.

Equity price risk

The Group's investment in listed and unlisted equity and preference securities are susceptible to market price risk arising from uncertainties about the future value of investment in these securities. The Group manages these price risks through strategic investments and placing limits on individual investments. The investments reports are submitted to the senior management and the Board reviews and approves these investment decisions

Sensitivity risk - equity price risk

The Group's investment in listed equity shares on Bombay Stock Exchange in India, for such investments being classified as fair value through other comprehensive income, an increase of 2% in BSE index at the reporting

| Asat | 31 March 2022 | As at 3 | 1 March 2021 |
|----------|---------------|----------|--------------|
| Increase | Decrease | Increase | Decrease |

vices

SISSY





Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

Management assessment of recoverability of trade receivables

recognised the Impairment loss. Further, the Group is closely monitoring the developments across various business lines. Basis the aforesaid detailed assessment made by Management, provision made towards trade receivables Trade receivables forms a significant part of the financial assets carried at amortized cost. The Group has performed detailed customer wise specific assessment of recoverability of the trade receivables and has accordingly is considered adequate.





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

ii. Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers. The carrying amount of following financial assets represents the maximum credit exposure:

- a. Trade receivables
- b. Unbilled receivables
- c. Cash and bank balances
- d. Loans receivables
- e. Other financial assets

Trade receivables

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer and the geography in which it operates. Credit risk is managed through credit approvals and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business.

The Group Companies individually monitors the sanctioned credit limits as against the outstanding balances. Accordingly, the Group makes specific provisions against such trade receivables wherever required and monitors the same at periodic intervals.

The Group establishes an allowance for impairment that represents its estimate of expected losses in respect of trade receivables.

The maximum exposure to credit risk for trade receivables was as follows

| Particulars | | As at |
|------------------------|--------------------|---------------|
| | 31 March 2022 31 N | 31 March 2021 |
| Trade receivables | 637.63 | 716.61 |
| Habillad managinahlan | | 10:01 |
| Oliolitica receivables | 725.94 | 819 94 |
| | | |
| | 1,403,57 | 1 536 55 |

Impairment analysis

The ageing of trade receivables that were not impaired was as follows:

| Particulars | | Asat |
|----------------------|--------------------|---------------|
| | 31 March 2022 31 1 | 31 March 2021 |
| Less than I year | L | 409.47 |
| 1-2 years | | 78.32 |
| 2-3 years | | 118.06 |
| More than 3 years | 140.68 | 110.77 |
| Unbilled receivables | | 819.94 |

536.56

1,403.57

The movement in the allowance for expected credit losses in respect of trade receivables during the year was as follows:

| Particulars | | | AS M | AS AL |
|--------------------------------------|---------|-------|---------------|---------------|
| | | | 31 March 2022 | 31 March 2021 |
| Balance at the beginning of the year | | | 283.00 | 52.14 |
| Impairment loss recognized | | | (12.79) | 253.82 |
| Amounts written off | 001 | ollho | (67 72) | (90 00) |
| Balance at the end of the year | COOON S | 1000 | 207.40 | 363.00 |
| | | (0) | 401.43 | 707.00 |

ervices

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

32 Financial instruments - Fair values and risk management (continued)

ii. Credit risk (continued)

Unbilled receivables

Unbilled receivables forms a significant part of the financial assets carried at amortized cost. The Group has performed detailed customer wise specific assessment of recoverability of the unbilled receivables and has accordingly recognised the Impairment loss. Further, the Group is closely monitoring the developments across various business lines. Basis the aforesaid detailed assessment made by Management, provision made towards unbilled receivables is considered adequate

The movement in the allowance for expected credit losses in respect of unbilled receivables during the year was as follows:

| Particulars | Asat | Asat |
|--------------------------------------|---------|--------------|
| | | 1 March 2021 |
| Balance at the beginning of the year | | |
| Impairment loss recognized | 1.48 | 42.75 |
| Amounts utilised | (35.85) | , |
| Balance at the end of the year | 8.38 | 42.75 |
| | | |

Cash and cash equivalents and other bank balances

The cash and cash equivalents and other bank balances are held with bank and financial institution counterparties with good credit rating,

Loans receivables

These represents security deposits given towards office premises taken on lease under contractual arrangement and EMD deposit for participation in tender.

iii. Liquidity risk

liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group approach to managing Group reputation,

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements:

As at 31 March 2022

| | | | | Contra | Contractual cash flows | |
|---|---------------------------------------|-----------------|-------------|-----------|-----------------------------|--------|
| Particulars | | Carrying amount | 0-12 months | 1-2 years | 2-5 years More than 5 years | Total |
| Financial liabilities Trade and other payables | | 290.20 | 290.20 | | | 290.20 |
| Other current financial liabilities | | 91.55 | 91.55 | | | 91.55 |
| | P. ASSOCI | 381.75 | 381.75 | 4 | 31 31 | 381.75 |
| As at 31 March 2021 | WES* | | 195 | | | |
| | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | | W IN | Contra | Contractual cash flows | |
| | To a second | | | | | |

(All amounts are in Indian Rupees in millions, unless otherwise stated) Notes to Consolidated financial statements (continued) Medi Assist Healthcare Services Limited

Particulars

Total

2-5 years More than 5 years

1-2 years

0-12 months

Carrying amount

334.88 508.60

334.88

508.60

334.88 173.72 508.60

Other current financial liabilities Trade and other payables Financial liabilities

| | 1 |
|--|---|
| | |
| | 1 |
| | |







Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

33 Capital management

The Group policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The Capital Management policy focusses to maintain an optimal structure that balances growth and maximizes shareholder value.

The Group's adjusted net debt to equity ratio were as follows.

| Particulars | As at | As at |
|--|---------------|---------------|
| r ai dediais | 31 March 2022 | 31 March 2021 |
| Total borrowings | | 2.0 |
| Less : Cash and cash equivalent | (145.95) | (633.89) |
| Adjusted net debt (restricted to Nil) | | - |
| Total equity (Including NCI) | 3,392.86 | 2,925.50 |
| Adjusted net debt to adjusted equity ratio | | |

The Group has Nil borrowing as at 31 March 2022.

34 Segment reporting

(a) Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that business enterprises reporting information about the operating segment and related disclosure made by the Chief Operating Decision Maker (CODM).

The Group is engaged in the business of Health Benefits Administration and Health Management Services, The CODM reviews these activities under the context of Ind AS 108 Operating Segment as one single primary segment to evaluate the overall performance assessment of entity's operating segment.

(b) Information about major customers (external customers):

The following is the transactions by the Group with external customers individually contributing 10 per cent or more of the Group's revenue from operations:

- (i) For the year ended 31 March 2022, revenue from operations of two customers of the Group represented approximately 42% and 15%, of the Group's revenue from operations.
- (ii) For the year ended 31 March 2021, revenue from operations of two customers of the Group represented approximately 36% and 17%, of the Group's revenue from operations.



(This space is intentionally left blank)

Bho.



Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

35 Movement in deferred tax assets (net)

i. Movement in deferred tax balances for the year ended 31 March 2022

| Particulars | Deferred tax assets/ (liabilities) as at 1 April 2021 | Recognized in Consolidated statement of profit and loss | Recognized in OCI | Deferred tax (liabilities)/ assets as at 31 March 2022 | Deferred tax assets | Deferred tax liabilities |
|--|---|---|----------------------|--|---------------------|-----------------------------|
| Property plant and equipment and other intangible assets | (47.56) | 18.42 | | (29.14) | | (29.14) |
| Employee benefits | 29.91 | 2.95 | 7.06 | | 39.92 | |
| Allowance for expected credit losses | 90.63 | (28.19) | | | 62.44 | |
| Financial liabilities | , | • | | • | • | |
| Financial assets | 5.30 | (14.56) | 0.62 | (8.64) | | (8.64) |
| Security deposit | 1.35 | (0.57) | | 0.78 | 0.78 | |
| Other items | 4.12 | 2.30 | * | 6.42 | S. | |
| Temporary differences on expenses | 2.11 | 2.70 | 3 | 4.81 | 4.81 | |
| Right-of-use assets | (67.57) | | | (50.55) | | (50.55) |
| Lease Liability | 88.13 | (18.97) | 30 | 69.16 | 69.16 | |
| | 106.42 | (18.90) | 7.68 | 95.20 | 183.53 | (188 11) |

ii. Movement in deferred tax balances for the year ended 31 March 2021

| Particulars | Deferred tax assets/ (liabilities) as at 1 April 2020 | Recognized in Consolidated statement of profit and loss | Recognized in OCI | Deferred tax (liabilities)/ assets as at 31 March 2021 | Deferred tax assets | Deferred tax liabilities |
|--|---|---|----------------------|--|---------------------|-----------------------------|
| Property plant and equipment and other intangible assets | (59.22) | 11.66 | | (47.56) | | (47.56) |
| Employee benefits | 25.63 | 2.80 | 1.48 | 29.91 | 29.91 | |
| Allowance for expected credit losses | 19.68 | 70,95 | ٠ | 90.63 | 90.63 | |
| Financial liabilities | (0.06) | | 100 | | | • |
| Financial assets | 7.75 | 2.98 | (5.43) | 5.30 | 5.30 | • |
| Security deposit | 1.62 | | • | | 1.35 | • |
| Other items | 3.58 | 0.54 | | 4.12 | 4.12 | ٠ |
| Femporary differences on expenses | | 2.11 | 29 | 2.11 | 2.11 | |
| Right-of-use assets | (88.28) | 20.71 | | (67.57) | | (67.57) |
| Lease Liability | 107.59 | (19.46) | • | 88.13 | 88.13 | |
| | 18.29 | 92:08 | (3.95) | 106.42 | 221.55 | (11513) |

The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the grant tax assets and deferred tax assets and deferred tax liabilities relate to (a)

deferred income tax assets. The recoverability of Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recover deferred income tax assets is based on estimates of taxable income and the period over which deferred income tax assets will be recovered (P)

33

Notes to Consolidated financial statements (continued) Medi Assist Healthcare Services Limited

(All amounts are in Indian Rupees in millions, unless otherwise stated)

36 Tax expense relating to continuing operations

(a) Amounts recognised in consolidated statement of profit and loss

| Particulars | For the year ended | For the year ended |
|---|---------------------------------------|--------------------|
| Current tax | 96 601 | 20000 |
| | 07:761 | 207.00 |
| Adjustment of tax relating to earlier years | (38.99) | (4.66) |
| Deferred tax (credit) charge | 18 93 | (50 55) |
| Tax expense for the year | e e e e e e e e e e e e e e e e e e e | 20.000 |
| | 1/7.70 | 229.37 |

(b) Amounts recognised in other comprehensive income

| | For the year | For the year ended 31 March 2022 | | For the | For the year ended 31 March 2021 | 21 |
|--|--------------|----------------------------------|------------|------------|----------------------------------|--------------------|
| | Before tax | Tax benefit | Net of tax | Before tax | Tax benefit | Net of tax |
| Items that will not be reclassified subsequently to the statement of profit and loss | | | | | | |
| Remeasurements of defined benefit (assets)/ liabilities | (28.06) | 7.06 | (21.00) | (5.87) | 1.48 | (4.39) |
| Net gain on financial assets measured at fair value through OCI | (5.34) | 0.62 | (4.72) | 13.93 | (5.43) | 8.50 |
| | (33.40) | 2.68 | (25.72) | 90'8 | (3.95) | 4.11 |
| Reconciliation of effective tax rate | | | | | | |
| Particulars | | | | | For the year ended | For the year ended |
| | | | | | 31 March 2022 | 31 March 2021 |
| Profit before tax for the year from continuing operations | | | | | 806.87 | 610.41 |
| Domestic tax rate | | | | | 25.17% | 25.17% |
| Tax using company's domestic rate | | | | | 203.09 | 153.64 |
| Tax effect of: | | | | | | |
| Exempt income | | | | | , | (8911) |
| Expenses not allowed for tax purpose | | | | | 10.03 | 6.07 |
| Tax expense of previous years | | | | | (38.99) | (4.66) |
| Effect of tax base of goodwill non deductible for amortisation* | | | | | | 23.16 |
| Demerger expenses | | | | | (0.26) | (920) |
| Tax effect of dividend income from subsidiary Company | | | | | | 78.03 |
| Others | | | | | (1.67) | (14.91) |
| | | | | l. I. | 172.20 | 229.37 |
| Current tax | | | | | 192 26 | 289.08 |
| Income tax (credit)/ charge for carlier years | | | | | (38 00) | (4 66) |
| Deferred tax charge(credit) | | | | | 18.93 | (55.05) |

During the year 19-20, the Group decided to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 from the FY 19-20 and onwards.

* Pursuant to the Finance Bill enacted in February 2021, the amortisation of goodwill will not be allowed as tax deduction with effect from 1 April 2020, hence the corresponding tax base of goodwill as at 1 April 2020 became Nil. Therefore, deferred tax charge for the year ended 31 March 2021 includes Rs. 23.16 million being the deferred tax liability recognised by the subsidiary on the difference between the book base and tax base of goodwill consequent upon enactment of above provisions.





ervices

ISISSA

Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

37 (i) Discontinued Operations - Card Processing Business

A During the Financial year 2020-21, the Group has decided to discontinue the business operations pertaining to card processing which are mainly generating from government contract. The Group has disclose the discontinuation of card processing business as discontinued operations as per the requirement of Ind AS 105 ' Non current asset held for sale and Discontinued operation'. The Group has re-represented the comparative information due to the discontinued operations.

| Particulars | For the year ended | For the year ended |
|---|--------------------|---|
| Revenue | | THE PERSON NAMED IN CO. |
| Revenue from operations | 118.11 | 366.78 |
| Total income | 118.11 | 366.78 |
| Expenses | | |
| Employee benefits expenses | | 18.51 |
| Other expenses | 109.29 | 494.83 |
| Total expenses | 109.29 | 513.34 |
| Profit/ (Loss) before tax from a discontinued operation | 8.82 | (146.56) |
| Tax Credit Related to pre-tax profit/(Lose) | | *************************************** |
| | (2.22) | 32.23 |
| Profit (Loss) after tax from a discontinued operation | 09'9 | (114.33) |
| | | |

B Net cash flows attributable to the discontinued operations

| Particulars | Notes | For the year ended 31 March 2022 | For the year ended |
|--|-------------|-------------------------------------|--------------------|
| Net cash generated/ (used in) from operating activities | (4) | 5000 | 35.00 |
| Common district (in the control of t | (3) | 67.66 | 94.33 |
| Net cash generated/ used in investing activities | Althoat (B) | 31 | , |
| Net cash generated/ used in financing activities | (C) (S) | | |
| Notice of the second se | 317 | | |
| iver mer ease, (neer ease) in eash and eash equivalents A-B-C) | vic | 99.23 | 94.35 |
| * | es | | |
| Students | (A) | | |
| Seined Accounting | 2 * 2 | | |

Medi Assist Healthcare Services Limited Notes to Consolidated financial statements (continued) (ii) Discontinued Operations - Pre-policy checkup services



A During the Financial year 2021-22, the Group has decided to discontinue the business operations pertaining to pre-policy checkup services. The Group has disclose the operation'. The Group has re-represented the comparative information due to the discontinued operations. discontinuation of pre-policy checkup business as discontinued operations as per the requirement of Ind AS 105 ' Non current asset held for sale and Discontinued

| Tax Credit Related to pre-tax profit/(loss) (0.31) | Profit/ (Loss) before tax from a discontinued operation | Total expenses | Expenses Other expenses | 1 otal income | Revenue from operations 25.05 | For the year ended 31 March 2022 |
|--|---|----------------|-------------------------|---------------|-------------------------------|-------------------------------------|
| | | | | | | For the year ended 31 March 2021 |

B Net cash flows attributable to the discontinued operations

| (55.63) | 11.66 | | Net increase/ (decrease) in cash and cash equivalents (A+B+C) |
|--------------------|--------------------|-------|---|
| | | (C) | Net cash generated used in linancing activities |
| • | , | (B) | Not cast generated used in investing activities |
| (55.63) | 11.66 | (A) | Net cash generated/used in investing activities |
| 31 March 2021 | 31 March 2022 | | No. 1 |
| For the year ended | For the year ended | Notes | Particulars |

Assis

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

38 Expenditure incurred in foreign currency

| Particulars | For the year ended 31 March 2022 | For the year ended 31 March 2021 |
|-----------------------------|-------------------------------------|-------------------------------------|
| Fees for technical services | 2.86 | 1.02 |

39 Corporate Social Responsibility ("CSR")

Where the company covered under section 135 of the 2013 Act, the following shall be disclosed with regard to CSR activities:-

| Particulars | For the year ended 31 March 2022 | |
|---|--|---|
| (a) amount required to be spent by the company during the year | 10.70 | 12.49 |
| (b) amount of expenditure incurred | 10.70 | 13,08 |
| (c) shortfall at the end of the year | | (0.59) |
| (d) total of previous years shortfall | | |
| (e) reason for shortfall | | |
| (f) nature of CSR activities | employment enhancing vocational skills by way of providing training in a wide array of functional areas to persons at various | activities is livelihood enhancement and |
| (g) details of related party transactions* | | |
| (h) where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately. | d - | |

40 Related party disclosures

In compliance with Ind AS 24 - "Related Party Disclosures", as notified under Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 the required disclosures are given below:

(A) Names of the related parties and description of relationship

(i). Subsidiary

Medi Assist Insurance TPA Private Limited

(ii). Key management personnel

Dr. Vikram Jit Singh Chhatwal - Chairman cum Whole Time Director w.e.f. 1st March 2021

Satish Gidugu - Whole Time Director and CEO w.e.f. 1st March 2021

Vishal Vijay Gupta - Director

Sanjay Kalra - Independent Director - Retired w.e.f. 11th March 2021 Himani Atul Kapadia- Independent Director w.e.f. 15th March 2021

Gaurav Sharma - Nominee Director

Gopalan Srinivasan - Independent Director w.e.f. 15th March 2021 Anil Chanana - Independent Director w.e.f. 15th March 2021 Dr. Ritu Niraj Anand - Independent Director w.e.f. 15th March 2021 Ananda Mukerji - Independent Director w.e.f. 15th March 2021 Mathew George - Chief Financial Officer w.e.f 3rd March 2021

Megha Matoo - Chief Compliance Officer and Company Secretary w.e.f 5th March 2021

(iii). Entity having significant influence

Medimatter Health Management Private Limited

(iv). Entities under common control

Phasorz Technologies Private Limited Mandala Wellness Private Limited ('MWPL')

- (MWPL Merged with Phasorz Technologies Private Limited w.e.f I

(v). Entities having common director

Buddhimed Technologies Private Limited





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

40 Related party disclosures (continued)

(B) Summary of transactions with the above related parties are as follows:

| Particulars | Notes | For the year ended 31 March 2022 | For the year ender 31 March 202 |
|---|-------|-------------------------------------|------------------------------------|
| Consultancy fees paid to | | | |
| Medimatter Health Management Private Limited | | | 0.90 |
| Buddhimed Technologies Private Limited | | | 2.00 |
| Support service income from | | | |
| Phasorz Technologies Private Limited | | 39.90 | 58.60 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Health Management services from | | | |
| Phasorz Technologies Private Limited | | | 36.74 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Support service fee paid to | | | |
| Phasorz Technologies Private Limited | (a) | 23.86 | 47.38 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Interest on debentures | | | |
| Medimatter Health Management Private Limited | | | 0.23 |
| Conversion of Redeemable preference shares to Series B CCPS | | | |
| Medimatter Health Management Private Limited | | | 523.00 |
| Conversion of Series B CCPS to equity shares | | | |
| Medimatter Health Management Private Limited | | * | 523.00 |
| Advance received | | | |
| Phasorz Technologies Private Limited | | | 61.6 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Reimbursement of expenses to | | | |
| Phasorz Technologies Private Limited | (a) | 153.12 | 186.28 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) Health screenings | | | |
| Accrued Expenses | | | |
| Phasorz Technologies Private Limited | (a) | | 5.29 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Reimbursement of charges from | | | |
| Phasorz Technologies Private Limited | | | |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Facilities and other expenses | | 12.82 | 4,30 |
| Expenses cross charge | (b) | | 73.12 |
| Repayment of Non Convertible Debenture | | | 2020 |
| Medimatter Health Management Private Limited | | 22 | 2.00 |
| Business promotion expense (Accrued) | | | |
| Phasorz Technologies Private Limited | | 24.50 | |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Interest income | | | |
| Phasorz Technologies Private Limited | | | 33.45 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | |
| Reimbursement of expense to Director | | 0.24 | 1.52 |
| Compensation of key management personnel | | | |
| Short term employee benefits | (c) | 42.04 | 27.42 |
| Director sitting fees | | 5.18 | 0.83 |
| Commission to independent directors | | 2.50 | |

- (a) These transaction are carried out with MWPL by the subsidiary Company through the Holding Company, who acted on behalf of MWPL.
- (b) The expenses reflected in Consolidated Statement of Profit and Loss are net of those cross charged to the Mandala Wellness Private Limited and that the management is confident of recovering the entire other receivable balance including the cross charge amount.
- In the opinion of the management, all transactions were made on normal commercial terms and conditions and at arm's length price.
- (c) As the liability for gratuity and compensated absence is provided on an actuarial basis for the Group as a whole, the amount pertaining to Director is not ascertainable and, therefore not included above.





Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

40 Related party disclosures (continued)

(C) The Group has the following amount due from/ to related parties

| Particulars | | | For the year ended 31 March 2022 | For the year ender 31 March 202 |
|--|---------------|--------------------|-------------------------------------|------------------------------------|
| Amount receivable towards rendering of services | | | | |
| (i) Trade receivables | | | | |
| Phasorz Technologies Private Limited | | | 101.81 | 48.42 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | (| | | |
| (ii) Unbilled receivables | | | | |
| Phasorz Technologies Private Limited | | | 30.00 | 52.43 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) |) | | | |
| Amount payable towards rendering of services (Trade payables) | | | | |
| Phasorz Technologies Private Limited | | | 64.31 | 50.70 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | | |
| Other payables | | | | |
| Phasorz Technologies Private Limited | | | 37.50 | 58.64 |
| - (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | i. | | 27,00 | 30.04 |
| Accrued expenses (Net of advance) | | | | |
| Phasorz Technologies Private Limited | | | 14.50 | |
| - (MWPL Merged with Phasorz Technologies Private Limited w.c.f 1 April 2022) | È | | 1 575747 | |
| Other receivables | | | | |
| Phasorz Technologies Private Limited | | | 33.36 | 145.22 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | | |
| Advance balance | | | | |
| Phasorz Technologies Private Limited | | | | 61.60 |
| (MWPL Merged with Phasorz Technologies Private Limited w.e.f 1 April 2022) | | | | |
| Other financial liabilities | | | | |
| Employee benefits payable | | | 14.45 | 6.70 |
| Reconciliation of movements of liabilities to cash flows arising from financing | g activities | | | 11 2000 - 1111-0 114.114 |
| | As at | Non-cash | changes | (Rs in millions) As at |
| Particulars | 31 March 2021 | Fair value changes | Repayment | 31 March 2022 |
| Non-current financial liabilities - Borrowings | | | - Accomplisation | DI Maich 2022 |

(This space is intentionally left blank)

As at

1.77

31 March 2020



Non-current financial liabilities - Borrowings

Particulars



(2.00)

Repayment

Non-cash changes

0.23

Fair value changes

(Rs in millions)

31 March 2021

As at

Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

42 Micro, small and medium enterprise

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum in accordance with the 'Micro, Small and Medium Enterprises Development Act, 2006 ('the Act'). Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2022 and 31 March 2021 has been made in the consolidated financial statements based on information received and available with the Group. Further in view of the Management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act is not expected to be material. The Group have following dues to micro and small enterprises as at 31 March 2022.

The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year:

| Particulars | As at 31 March 2022 | As a 31 March 2021 |
|---|------------------------|-----------------------|
| The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year: | | |
| Principal | 32.32 | 31.39 |
| Interest | 1.20 | 0.11 |
| The amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year. | | |
| The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006. | 4 | |
| The amount of interest accrued and remaining unpaid at the end of each accounting year. | 1.20 | 0.11 |
| The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006. | 12 | |

43 The Group does not have any long-term contracts including derivative contracts for which there are any material foreseeable losses.

44 Non-current assets held for sale

| Particulars | Notes | As at 31 March 2021 |
|---|-------|------------------------|
| Other intangible assets IHX platform * | 6 | 12.44 |
| | τ, | 12.44 |

^{*} The Board meeting held on 7 December 2020, the Board of Directors of the Group granted in-principle approval for sale of IHX platform (included under other intangible assets) and consequently, as per the requirements of Ind AS 105 - Non Current Assets held for Sale and Discontinued Operations, the Group has classified the assets as at 31 March 2021 as Non-current assets classified as held for sale. The Management is reasonably certain the fair value less cost to sale will be higher than the carrying value of the non-current asset held for sale.

45 Additional Regulatory Information required under Schedule III

(i) Details of benami property held

No proceedings have been initiated on or are pending against the Group for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

(ii) Borrowing secured against current assets

The Group has no borrowings from financial institutions on the basis of security of current assets.

(iii) Wilful defaulter

The Group has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

(iv) Relationship with struck off companies

The Group has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956.

(v) Compliance with number of layers of companies

The group has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(vi) Compliance with approved scheme(s) of arrangements

The Group has not entered into any approved scheme of arrangement which has an accounting impact in current or previous financial year.





Medi Assist Healthcare Services Limited
Notes to Consolidated financial statements (continued)
(All amounts are in Indian Rupces in millions, unless otherwise stated)

| 50 | Ratios | | | | | | | | | | | |
|------------|--|----|--------------------------------------|---------------|------|---------------|------|---------------|---|--|---------------------------------------|--|
| Sr. No. | Ratio | | Numerator / denominator | 31 March 2022 | | 31 March 2021 | | 31 March 2021 | | % Change from 31 March 2021 to 31 March 2022 | Reason for change by more than 25% | |
| 1 | Current ratio | - | CHITEIN BOOK | 4,273.04 | 1.82 | 3,704.75 | 1.70 | 8% | Increase ratio due to docrease is | | | |
| <u>.</u> | A CAST LANGE AND A CAST | | Current liabilities | 2,342.03 | 1.04 | 2,185.20 | 1.70 | - | current asset and current liabilities | | | |
| 2 | Debt- Equity Ratio | | Total Debt | 274.78 | 0.08 | 353.00 | 0.17 | 0.17 | 0.12 | 750 | Decrease ratio due to repayment o | |
| | | | Shareholder's equity | 3,392.86 | 0.08 | 2,925.50 | 0.12 | -3376 | debt i.e lease liability | | | |
| 3 | Return on Equity ("ROE") | - | Net profits after taxes - Preference | 634.67 | 0.20 | 380.06 | 0.15 | 34% | Increase in net profit after tax due to | | | |
| | 257 miles 2500 (00 miles file | | Average shareholder's equity | 3,159.18 | 0.20 | 2,530.54 | 0.15 | 34% | increase in income | | | |
| 4 | Inventory Tursover Ratio | - | Cost of Goods sold | - | | - | | | | | | |
| | | | Average Inventory | | | | | | | | | |
| 5 | Trade receivables turnover ratio | | Net Credit Sales | 3,938.10 | | 3,227.41 | | | Increase ratio due to improvement in | | | |
| | | - | Average Accounts Receivable | 1,199.25 | 3.28 | 1,324.03 | 2.44 | 35% | collection of receivables | | | |
| 6 | Trade payables turnover ratio | - | Net Credit Purchases | 1,469.44 | 100 | 1,037.39 | 2.00 | 2.70 | | Increase ratio on account of reduction | | |
| | Prof. Land and Control Control Control Control | _ | Average Accounts Payable | 312.54 | 4.70 | 371.47 | 2.79 | 68% | in payables | | | |
| 7 | Net capital turnover ratio | Γ. | Net Sales | 3,938.10 | 2.04 | 3,227.41 | | -201 | | | | |
| | ne-sear environmental | _ | Working Capital | 1,931.01 | 2.04 | 1,519.55 | 2.12 | -4% | | | | |
| 8 | Net profit ratio | - | Net Profit after tax | 634.67 | 9.16 | 380.06 | 0.12 | | | 0.12 | | |
| | | | Net Sales | 3,938.10 | 9.10 | 3,227.41 | | 375 | Increase in net profit after tax | | | |
| 9 | Return on capital employed (ROCE) | | Earning before interest and taxes | 836.37 | 0.25 | 667.67 | 0.23 | 8% | Increase ratio on account of increase in earning before interest and taxes | | | |
| | | | Capital Employed | 3,392.86 | | 2,925.50 | | | | | | |
| 10 | Return on investment | - | Income generated from invested funds | 87.20 | 9.06 | 61.97 | 0.08 | -27% | Investment only in FD, short term fund | | | |
| | The Assessment Control of the Control | | Average invested funds in treasury | 1,487.97 | 4.00 | 773.85 | 0.08 | *4176 | and altra short term fund | | | |







Notes to Consolidated financial statements (continued)

(All amounts are in Indian Rupees in millions, unless otherwise stated)

45 Additional Regulatory Information required under Schedule III (continued)

(vii) Utilisation of borrowed funds and share premium

- The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
- II The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries

(viii Undisclosed income

There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

(ix) Details of crypto currency or virtual currency

The Group has not traded or invested in crypto currency or virtual currency during the current or previous year.

(x) Valuation of PP&E, intangible asset and investment property

The Group has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.

- (xi) The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- 46 The COVID-19 pandemic has significantly impacted global economies, resulting in workforce and travel restrictions, supply chain and production disruptions and reduced demand and spending across many sectors. The Group has continued to adopt measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Group has considered internal and external information while finalizing various estimates in relation to its financial statement captions upto the date of approval of the financial statements by the Board of Directors. The Group will continue to closely monitor any material changes to future economic conditions.

47 Exceptional item

The Group has incurred Rs.101.28 million (Current year - Rs. 75.27 million; Previous year - Rs.26.01 million) towards IPO expenses. During the year, certain selling share holders has agreed to reimburse these expenses in proportion to their shares offered for sale at the time of the IPO in previous year and to this extent resolution is passed in the Board meeting. Accordingly Rs.26.01 million expenses has been credited to the Statement of profit of loss (as an exceptional item) along with current year expenditure of Rs.75.27 mil and disclosed as recoverable from selling shareholders (Refer note 12(e)).

48 Events after the reporting date

The Group evaluated all events or transactions that occurred after the balance sheet date through, the date at which the financial statements were available to be issued and determined that there are no other items to disclose except those already disclosed in the financial in earlier notes.

49 The Code on Social Security 2020

The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued. The Group will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective and the related

rules to determine the financial impact are published.

50 Previous year figures have been regrouped/ reclassified to confirm presentation as per Ind AS and as required by Schedule III of the Act.

The notes referred to above form an integral part of these consolidated financial statements.

ASSO

ered Acco

As per our report of even date,

for MSKA & Associates

Chartered Accountants

Firm's Registration Number: 105047W

Pradee sore Suresh

Partner

Membership Number: 216181

for and on behalf of the Board of Directors of Medi Assist Healthcare Services Limited CIN:U74900KA2000PLC027229

Dr. Vikram Jit Singh Chhatwal

Chairman and Whole Time Director

DIN: 01606329

Mathew George Chief Financial Officer

Place: Bengaluru Date: 23 September 2022 Saush Gidugu

Whole Time Director and CEO

DIN: 06643677

Megha Matoo

Chief Compliance Officer and Company Secretary

althca

ICSI Membership No: F-10665

Place: Bengaluru Date: 23 September 2022

Place: Bengaluru Date: 23 September 2022